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A B S T R A C T
Background
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Needle syringe programmes (NSP) and opioid substitution therapy (OST) are the primary interventions to reduce hepatitis C (HCV)
transmission in people who inject drugs. There is good evidence for the effectiveness of NSP and OST in reducing injecting risk
behaviour and increasing evidence for the effectiveness of OST and NSP in reducing HIV acquisition risk, but the evidence on the
effectiveness of NSP and OST for preventing HCV acquisition is weak.
Objectives
To assess the effects of needle syringe programmes and opioid substitution therapy, alone or in combination, for preventing acquisition
of HCV in people who inject drugs.
Search methods
We searched theCochraneDrug andAlcohol Register, CENTRAL, theCochraneDatabase of SystematicReviews (CDSR), theDatabase
of Abstracts of Reviews of Effects (DARE), the Health Technology Assessment Database (HTA), the NHS Economic Evaluation
Database (NHSEED), MEDLINE, Embase, PsycINFO, Global Health, CINAHL, and the Web of Science up to 16 November 2015.
We updated this search in March 2017, but we have not incorporated these results into the review yet. Where observational studies did
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not report any outcome measure, we asked authors to provide unpublished data. We searched publications of key international agencies
and conference abstracts. We reviewed reference lists of all included articles and topic-related systematic reviews for eligible papers.
Selection criteria
We included prospective and retrospective cohort studies, cross-sectional surveys, case-control studies and randomised controlled trials
that measured exposure to NSP and/or OST against no intervention or a reduced exposure and reported HCV incidence as an outcome
in people who inject drugs. We defined interventions as current OST (within previous 6 months), lifetime use of OST and high NSP
coverage (regular attendance at an NSP or all injections covered by a new needle/syringe) or low NSP coverage (irregular attendance at
an NSP or less than 100% of injections covered by a new needle/syringe) compared with no intervention or reduced exposure.
Data collection and analysis
We followed the standard Cochrane methodological procedures incorporating new methods for classifying risk of bias for observational
studies. We described study methods against the following ’Risk of bias’ domains: confounding, selection bias, measurement of
interventions, departures from intervention, missing data, measurement of outcomes, selection of reported results; and we assigned a
judgment (low, moderate, serious, critical, unclear) for each criterion.
Main results
We identified 28 studies (21 published, 7 unpublished): 13 from North America, 5 from the UK, 4 from continental Europe, 5 from
Australia and 1 from China, comprising 1817 incident HCV infections and 8806.95 person-years of follow-up. HCV incidence ranged
from 0.09 cases to 42 cases per 100 person-years across the studies. We judged only two studies to be at moderate overall risk of bias,
while 17 were at serious risk and 7 were at critical risk; for two unpublished datasets there was insufficient information to assess bias.
As none of the intervention effects were generated from RCT evidence, we typically categorised quality as low. We found evidence
that current OST reduces the risk of HCV acquisition by 50% (risk ratio (RR) 0.50, 95% confidence interval (CI) 0.40 to 0.63, I2 =
0%, 12 studies across all regions, N = 6361), but the quality of the evidence was low. The intervention effect remained significant in
sensitivity analyses that excluded unpublished datasets and papers judged to be at critical risk of bias. We found evidence of differential
impact by proportion of female participants in the sample, but not geographical region of study, the main drug used, or history of
homelessness or imprisonment among study samples.
Overall, we found very low-quality evidence that high NSP coverage did not reduce risk of HCV acquisition (RR 0.79, 95% CI 0.39
to 1.61) with high heterogeneity (I2 = 77%) based on five studies from North America and Europe involving 3530 participants. After
stratification by region, high NSP coverage in Europe was associated with a 76% reduction in HCV acquisition risk (RR 0.24, 95%
CI 0.09 to 0.62) with less heterogeneity (I2 =0%). We found low-quality evidence of the impact of combined high coverage of NSP
and OST, from three studies involving 3241 participants, resulting in a 74% reduction in the risk of HCV acquisition (RR 0.26 95%
CI 0.07 to 0.89).
Authors’ conclusions
OST is associated with a reduction in the risk of HCV acquisition, which is strengthened in studies that assess the combination of
OST and NSP. There was greater heterogeneity between studies and weaker evidence for the impact of NSP on HCV acquisition. High
NSP coverage was associated with a reduction in the risk of HCV acquisition in studies in Europe.
P L A I N L A N G U A G E S U M M A R Y
Interventions for reducing hepatitis C infection in people who inject drugs
Review question
We examine research on the effect of needle syringe programmes (NSP) and opioid substitution treatment (OST) in reducing the risk
of becoming infected with the hepatitis C virus.
Background
There are around 114.9 million people living with hepatitis C and 3 to 4 million people newly infected each year. The main risk for
becoming infected is sharing used needles/syringes. Almost half the people who inject drugs have hepatitis C. The provision of sterile
injecting equipment through NSPs reduces the need for sharing equipment when preparing and injecting drugs. OST is taken orally
2Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
and reduces frequency of injection and unsafe injecting practices. We examined whether NSP and OST, provided alone or together,
are effective in reducing the chances of becoming infected with hepatitis C in people who inject drugs.
Search date
The evidence is current to November 2015.
Study characteristics
We identified 28 research studies across Europe, Australia, North America and China. On average across the studies, the rate of new
hepatitis C infections per year was 19.0 for every 100 people. Data from 11,070 people who inject drugs who were not infected with
hepatitis C at the start of the study were combined in the analysis. Of the sample, 32% were female, 50% injected opioids, 51%
injected daily, and 40% had been homeless. Our study was funded by the National Institute of Health Research’s (NIHR) Public
Health Research Programme, the Health Protection Research Unit in Evaluation of Interventions, and the European Commission
Drug Prevention and Information Programme (DIPP), Treatment as Prevention in Europe: Model Projections.
Key results
Current use of OST (defined as use at the time of survey or within the previous six months) may reduce risk of acquiring hepatitis C
by 50%. We are uncertain whether high coverage NSP (defined as regular attendance at an NSP or all injections being covered by a
new needle/syringe) reduces the risk of becoming infected with hepatitis C across all studies globally, but there was some evidence from
studies in Europe that high NSP coverage may reduce the risk of hepatitis C infection by 76%. The combined use of high coverage
NSP with OST may reduce risk of hepatitis C infection by 74%.
Quality of the evidence
Quality of evidence ranged from moderate to very low because none of the studies used the gold standard design of randomised
controlled trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Current OST versus no OST
Patient or population: people who inject drugs
Settings: outpat ient
Intervention: current OST versus no OST
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No OST Current OST
HCV incidence adjusted
analyses
number of HCV seroconver-
sion
Follow-up: mean 440.5 per-
son-years
- - RR 0.50
(0.40 to 0.63)
6361
(12 studies)
⊕⊕©©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OST : opioid subst itut ion therapy; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level due to overall moderate risk of bias in 2 studies, overall serious risk of bias in 6 studies, 2 studies at
overall crit ical risk of bias in 2 studies; not enough information to make judgment in 2 studies.
bUpgraded one level due to large magnitude of the ef fect: RR: 0.5.
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B A C K G R O U N D
Description of the condition
The number of people exposed to hepatitis C continues to increase
globally, with an estimated 114.9 million people living with anti-
bodies to hepatitis C (Gower 2014), 3 to 4 million people newly
infected each year and 350,000 deaths occurring annually (Mohd
Hanafiah 2013; Perz 2006). There were an estimated 35 million
people livingwith human immunodeficiency virus (HIV) in 2014.
Emerging evidence suggests that HIV transmission has declined
since 2001 and more people are receiving treatment (UNAIDS
2014). Co-infection with hepatitis C (HCV) among people living
with HIV is a major global public health concern, with an esti-
mated 4 million co-infected people (Platt 2016). Among people
who inject drugs (PWID), sharing needle/syringes is the main risk
factor for infection with HIV andHCV. Additional risks for HCV
acquisition in this population include sharing drug preparation
containers, filters, rinse water and backloading (a method of shar-
ing drugs by transferring them from the needle of one syringe into
the barrel of another) (Pouget 2012; Strathdee 2010).
Description of the intervention
NSPs are often a first point of contact with health services for
PWID. They provide support tominimise drug and sexual risk-re-
lated harms, including the provision of clean needles/syringes and
condoms so as to prevent bloodborne virus transmission, bacterial
infections and other adverse health outcomes. By maximising the
amount of clean injecting equipment in circulation, it is possible
to minimise the time that contaminated equipment remains in use
and the proportion of unsafe injections (Bluthenthal 2007; Kaplan
1992). NSPs operate through a range of modalities including via
fixed sites, outreach, peer PWID networks, vending machines and
pharmacies. Engaging in behaviours that are socially stigmatised
and illegal, PWID often have high rates of unemployment, home-
lessness and incarceration. NSPs also provide access to longer-term
support by referring clients to medical, drug treatment or social
support services.
Drug treatment for opioid addiction and dependence also encom-
passes a range of strategies to manage injecting drug use and re-
duce associated harms, including medication-assisted treatment
(MAT) such as opioid substitution therapy (OST), MAT plus
psychosocial approaches, and residential rehabilitation. The most
commonly prescribed forms of OST are the opioid agonist treat-
ments methadone maintenance therapy (MMT) and the partial
agonist buprenorphinemaintenance treatment (BMT). Buprenor-
phine plus the antagonist naloxone (licensed as ’Subuxone’) is also
increasingly popular. OST is prescribed to dependent users to di-
minish the use and effects of illicitly acquired opioids. It is usually
taken orally and therefore reduces the frequency of injection and
unsafe injecting practices (Tilson 2007). As a treatment for opioid
dependence, OST has been shown to increase health and social
functioning, decrease crime and reduce the frequency of injection
and unsafe injecting practices (Gowing 2011; Vorma 2013). Ev-
idence suggests that OST is most effective when it is continuous
and provided at adequate doses (Amato 2013; Faggiano 2003).
International evidence supports the use of combination interven-
tions to prevent and treat HIV in PWID, with the provision of
NSP, OST, and HIV antiretroviral treatment as the key interven-
tions (Degenhardt 2010; WHO 2004). There is good evidence
that NSP andOST reduce injecting risk behaviours and increasing
evidence showing an impact on HIV incidence (Aspinall 2014;
MacArthur 2012). However, evidence of their impact onHCV in-
cidence amongPWID, in combinationor alone, is limited (Gibson
1999; Gibson 2001; Gowing 2011; Jones 2008; Palmateer 2010;
Turner 2011; Van Den Berg 2007).
How the intervention might work
Two recent systematic reviews of 12 observational studies esti-
mated that NSPs reduce HIV transmission among PWID by 48%
(95% confidence interval (CI) 3% to 72%), with strong evidence
that OST reduces HIV transmission by 54% (95% CI 33% to
68%) (Aspinall 2014; MacArthur 2012). However, none of the
evidence was based on randomised controlled trials and either
relied on cohort studies or cross-sectional studies that measured
OST or NSP exposure and HIV incident infections. Previous re-
views synthesising evidence of the efficacy of NSPs have focused
on HIV as the main outcome (Gibson 2001; Tilson 2007; Wodak
2004), thus failing to include all the available evidence on HCV
(Palmateer 2010).
A recent analysis of pooled data (N = 919) in a single country
examined the effect of NSP coverage on HCV incidence, defin-
ing coverage in terms of the proportion of injections covered by a
sterile syringe. This analysis suggested that high coverage of NSP
(’100% NSP’, i.e. obtaining at least one sterile syringes per injec-
tion) or OST (defined as receiving OST or not, either currently or
within the previous 6 months) can each reduce the risk of HCV
acquisition by 50%; and in combination by 80% (Turner 2011).
However, due to a small number of incident HCV cases (n = 40),
the efficacy estimate for 100% or more NSP among those not on
OST was weak (95% CI 0.22 to 1.12), and there was insufficient
power to investigate the existence of a dose-response relationship.
Another systematic review examined evidence from observational
studies on the impact of a range of risk reduction interventions
on HCV acquisition, including behavioural interventions, NSP,
and OST (Hagan 2011). This study measured the effect of NSP
use, defined inconsistently due to limited available evidence, as
any attendance at NSP or attendance at one point in time and
showed increased risk of seroconversion among NSP attenders.
Limitations of the studies included in this review were: substantial
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heterogeneity and lack of clarity and consistency in the measure-
ment of NSP use across studies.
A recent review on the effect of OST use on HIV transmission
identified many more studies than earlier Cochrane Reviews (
MacArthur 2012). Similarly, we suspected that not all evidence
on the effect of NSP on HCV transmission had been identified,
so extending previous reviews would strengthen the evidence base
as well as provide a more refined measure of NSP coverage that
accounts for frequency of attendance and degree to which NSPs
meet individuals’ requirements for sterile needle/syringes.
Why it is important to do this review
Evidence of the effect of NSP with and without OST on HCV
incidence is inconclusive (Palmateer 2010). Previous reviews have
failed to define the frequency of use of the intervention and/or the
coverage of the intervention (defined as the quantity of needles/sy-
ringes received per injection) (Hagan 2011), and a previous pooled
analysis had an insufficient sample size to accurately measure the
effect (Turner 2011). This review is needed in order to estimate
the effect of NSPs using a consistent definition of coverage and
examining impact with and without OST on HCV incidence, in
order to inform harm reduction policies aimed at reducing the
burden of HCV.
O B J E C T I V E S
To assess the effects of needle syringe programmes and opioid sub-
stitution therapy, alone or in combination, for preventing acqui-
sition of HCV in people who inject drugs.
We were specifically concerned with the following research ques-
tions.
1. How effective is OST alone for reducing HCV incidence in
PWID?
2. How effective are needle syringe programmes (NSP) with
and without OST for reducing HCV incidence in PWID?
3. How does the effect of NSP and OST vary according to
duration of treatment (i.e. for NSPs weekly attendance versus
monthly)?
4. How does the effect of NSP vary according to the type of
service (fixed site versus mobile; high coverage versus low
coverage)?
5. How does the effect of OST vary according to the dosage of
OST, type of substitution used and adherence to treatment?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), prospective and
retrospective cohort studies and case-control studies. We also fol-
lowed up and included prospective studies examining HCV in-
cidence in PWID that may have collected data regarding NSPs
and OST without reporting the data in the published study, or
which may have reported data as part of an adjusted analysis. For
these studies, we sought unpublished data relating to the impact of
NSP/OST on HCV transmission via contact with study authors.
We included studies only when authors provided these data.
We included cross-sectional surveys if they included a serological
measure of recent infection (e.g. through positive ribonucleic acid
(RNA) results on anti-body negative samples). We excluded cross-
sectional studies (including serial cross-sectional studies) report-
ing HCV prevalence alone. We excluded studies relying on self-
reported data for the outcome.
Types of participants
People who inject drugs (opioids and or stimulants). We excluded
studies enrolling participants undergoing opportunisticHCV test-
ing (outside of the study setting) and those relating to people who
inject drugs in the prison setting, since addiction services and treat-
ment provision in this setting differ significantly from community
and healthcare settings.
Types of interventions
Experimental interventions
• OST
• NSP
• NSP plus OST
Studies could be based in a drug treatment facility or in the wider
community, at a fixed site or mobile unit.
Exposure to OST was defined as continuous or interrupted treat-
ment, current, recent (previous six months or duration of HCV
observation period) or any past treatment with methadone or
buprenorphine.
Exposure to NSP was defined as the proportion of injections cov-
ered by a clean needle/syringe or attendance at an NSP. Where it
was not possible to estimate the proportion of injection covered
by a clean needle/syringe, we defined exposure accounting for fre-
quency of injection and the degree to which the NSP meets the
individual’s requirement for needles/syringes.
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Control intervention
• No OST
• Low coverage NSP or no NSP
Types of comparisons
1. OST versus no OST
2. High NSP coverage with no OST versus low coverage NSP
3. Low NSP coverage with no OST versus no NSP
4. Combined high/low NSP coverage with OST versus no
OST and low/no coverage NSP
Types of outcome measures
Primary outcomes
Our review focused on one primary outcome, HCV incidence,
and no other secondary outcomes. We excluded studies that did
not report on HCV incidence since they would have addressed
questions outside the main review question. Incidence of HCV
infection in PWID was measured via repeat testing such as detec-
tion ofHCVRNA positive amongHCV antibody negative results
or antibody avidity. We also included studies if they reported a
minimum of two HCV seroconversions (HCV antibody negative
to HCV antibody positive) in participants from tests conducted
at different time points.
Search methods for identification of studies
Methods to be used in this systematic review in relation to the
search strategies and approaches to data synthesis follow methods
applied in a similar review to assess the impact of OST on HIV
incidence (MacArthur 2012).
We identified papers in four ways. Firstly, we conducted two pri-
mary searches of the literature based on key search terms identi-
fied in reviews of the effect of OST and NSP on the risk of HIV
andHCV amongPWID (MacArthur 2012; Palmateer 2010). The
purpose of the two searches were to identify studies that measured
the impact of NSP/OST onHCV incidence (see Appendix 1) and
to identify longitudinal studies that measuredHCV incidence and
reported the impact of NSP/OST as part of an adjusted analysis
(see Appendix 2). The Cochrane Drugs and Alcohol Group Trials
Search Co-ordinator reviewed the search strategy and conducted
the search.
Electronic searches
We searched for relevant studies in the following sources.
• The Cochrane Drugs and Alcohol Group Specialised
Register of Trials (searched 16 November 2015).
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 11).
• The Cochrane Database of Systematic Reviews (CDSR)
(Cochrane Library, 2015, issue 11).
• The Database of Abstracts of Reviews of Effects
(DARE)(Cochrane Library, 2015, issue 11).
• The Health Technology Assessment Database (HTA)
(Cochrane Library, 2015, issue 11).
• The NHS Economic Evaluation Database (NHSEED)
(Cochrane Library, 2015, issue 11).
• MEDLINE (Ovid) (1966 to 16 November 2015).
• Embase (embase.com) (1974 to 16 November 2015).
• The Database of Abstracts of Reviews of Effects (DARE)
(Cochrane Library, searched 16 November 2015).
• Global Health (Ovid) (1974 to 16 November 2015).
• CINAHL (EBSCOhost) (1982 to 16 November 2015).
• Web of Science (1991 to 16 November 2015).
• PsycINFO (Ovid) (1985 to 16 November 2015).
We searched for ongoing clinical trials and unpublished trials via
searches of the following websites.
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).
This review fully incorporates the results of searches conducted up
to November 2015. We identified a further four reports of studies
in a search update conducted inMarch 2017.We have added those
studies to Studies awaiting classification and will incorporate them
into the review at the next update.
Searching other resources
We searched the publications of key international agencies includ-
ing the European Monitoring Centre on Drugs and Drug Addic-
tion, the European Centre for Disease Control, the National In-
stitute on Drug Abuse, the US Institute of Medicine, the United
Nations Office on Drugs and Crime Prevention and the World
Health Organization. We handsearched the reference lists of rele-
vant articles to identify additional relevant studies and contacted
experts in the field to identify ongoing research. We also searched
conference abstracts including the International Harm Reduction
Conference, International HIV/AIDS Society and the European
Association for the Study of the Liver conference. Finally we con-
tacted principal investigators and authors of prospective studies
that had examinedHCV incidence in PWID but had not reported
on the intervention exposure to see whether these data were avail-
able from unpublished sources.
There were no language or date restrictions, and we included peer
reviewed and non-peer reviewed papers.
Data collection and analysis
Selection of studies
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Two reviewers (LP, SM) independently screened all titles and ab-
stracts, resolving disagreements following discussion. Two review-
ers (LP, SM) independently screened full-text copies of relevant
articles to determine whether they met eligibility criteria for direct
inclusion or for contact of study authors. We resolved disagree-
ments by discussion or, where disagreements persisted, with adju-
dication by a third author (JR) to enable a consensus.
We had full-text papers in languages other than English translated
by individuals fluent in those languages. Where there were multi-
ple publications from the same study, or the same city or region,
we selected all published papers and extracted data from the study
with the greatest number of outcome events (i.e. HCV serocon-
versions).
Data extraction and management
One author (LP) extracted data using a data extraction form,which
two review authors had pre-piloted to determine suitability for
capturing study data and assessing quality. A second author (JR)
checked all data to assess the accuracy of data extraction. Data
extracted included:
• lead author;
• review title or unique identifier and date;
• eligibility for inclusion;
• reasons for exclusion;
• study aim(s);
• study design (included sampling methods, participant and
attrition rate);
• study location;
• study setting;
• proportion of participants who injected opioids;
• proportion of participants who injected stimulants;
• definition of exposure (recency of injecting);
• intervention (NSP provision; number of needles
distributed; frequency of injection; frequency of attendance;
methadone maintenance therapy or buprenorphine maintenance
treatment; delivery (e.g. continuous versus interrupted
treatment); duration; dose);
• additional interventions or incentives provided alongside
NSP/OST;
• participants (number in each intervention group; age, sex
and ethnicity);
• duration of follow-up in each treatment arm;
• outcome measure (HCV seroconversion) overall and by
NSP and OST exposure;
• unadjusted and adjusted effect size: incidence rate ratio
(IRR); odds ratio (OR); risk ratio (RR)hazard ratio (HR) and
precision (i.e. 95% confidence interval (CI));
• confounding factors used to adjust effect estimates
including high-risk behaviours (injecting risk behaviours,
frequency of injection, homelessness, experience of prison,
duration of injection, or age, poly drug use);
• background prevalence of HCV in the population;
• any other comments.
Assessment of risk of bias in included studies
We would have performed the ’Risk of bias’ assessment for RCTs
using the criteria in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). The recommended approach is a
two-part tool, addressing seven specific domains, namely sequence
generation and allocation concealment (selection bias), blinding
of participants and providers (performance bias), blinding of out-
come assessor (detection bias), incomplete outcome data (attri-
tion bias), selective outcome reporting (reporting bias) and other
sources of bias. The first part of the tool involves describing what
was reported to have happened in the study. The second part of
the tool involves assigning a judgment relating to the risk of bias
for that entry, in terms of low, high or unclear risk. To make these
judgments we would have used the criteria indicated by Higgins
2011, adapted to the addiction field. See Appendix 3 for details.
We would have assessed the risk of bias for unpublished estimates
by referring to the study methods in the corresponding published
paper.
We assessed the risk of bias in non-randomised studies using a
pilot version of a tool in development by the Methods Groups of
the Cochrane Collaboration (Sterne 2013). This was undertaken
as part of the formal piloting of the tool, in collaboration with its
developers. The seven-domain tool is an extension of the existing
tool for assessing risk of bias in randomised trials (Higgins 2011).
Three domains concern the pre-intervention phase or intervention
phase.
1. Baseline confounding. In assessing bias due to confounding
we considered there to be two critically important confounders:
duration of injecting or age; and frequency of injecting.
2. Selection of participants into the study.
3. Measurement of the intervention.
Four domains relate to the post intervention phase.
1. Departures from intended interventions (performance bias).
2. Missing data (attrition bias).
3. Measurement of outcomes or interventions (detection bias).
4. Selection of the reported results (outcome reporting bias).
Finally, we gave an overall risk of bias judgment at the study level
for each relevant outcome (see Appendix 4).
Since we were piloting a new ’Risk of bias’ tool, four contribu-
tors initially applied it independently to a sample of four studies.
We discussed and compared assessments to ensure consistent in-
terpretation of domains. Two people independently assessed the
remaining studies in the review and compared results. We resolved
disagreements by discussion.
Measures of treatment effect
When trials reported only effect estimates, we directly extracted
unadjusted and adjusted estimates reported as ORs, risk ratios
(RRs), IRRs or HRs with 95% CIs. When studies provided only
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incidence data, we estimated rate ratios and 95% CIs based on the
person-years of observation.We extracted effect estimates reported
asORs and took them as an approximation of the RR, even though
the incidence of HCV in included studies was variable (mean
18.7/100 person-years, range 0.09 to 42). In order to account
for this, we explored the impact of removing ORs on our overall
intervention effect in sensitivity analyses(MacArthur 2012; Zhang
1998).
Dealing with missing data
We contacted study authors if studies provided data regarding use
of NSP or the impact of drug treatment on HCV transmission
but insufficient detail regarding the precise form of treatment pro-
vided. We also contacted study authors if papers reported HCV
incidence data but no data regarding drug treatment or NSP. If we
could not obtain missing data, we excluded the studies from the
review.
Assessment of heterogeneity
We assessed heterogeneity via inspection of the forest plot and by
a Chi2 test to demonstrate whether the observed differences in
results were compatible with chance alone. We calculated tThe I
2 statistic was calculated to examine the percentage of variability
due to heterogeneity rather than to sampling error. We explored
heterogeneity through sensitivity and subgroup analysis.
Assessment of reporting biases
We used funnel plots (plots of the effect estimate from each study
against the sample size or effect standard error) to assess the po-
tential for bias related to the size of the trials, which could indi-
cate possible publication bias. We inspected funnel plot symmetry
when there were at least 10 studies included in the meta-analysis.
Data synthesis
We used a random-effects model for all analyses, allowing for het-
erogeneity between studies and converting all effect estimates into
RRs. We pooled adjusted and unadjusted effect estimates in sep-
arate meta-analyses. We used Review Manager 5 (RevMan 5) for
statistical analyses (RevMan 2014). We pooled data across differ-
ent observational study designs and assessed the potential asso-
ciation between study design and effect size, stratifying by study
design as well as in meta-regression analyses.
Subgroup analysis and investigation of heterogeneity
We examined heterogeneity with the I2 and Tau2 statistic and ex-
plored reasons for heterogeneity using univariable random-effects
meta-regression to evaluate the impact of the following covari-
ates: geographical region of study; recruitment setting (commu-
nity-based or treatment); percentage of female participants; main
drug injected; type of NSP; frequency of injecting; dose, duration
and adherence to NSP/OST (i.e. continuous or interrupted treat-
ment); and study design. There was insufficient information to
assess the impact of adherence to NSP/OST (i.e. continuous or
interrupted treatment).
Sensitivity analysis
We excluded studies that we assessed as being at critical risk of bias.
We also used sensitivity analysis to determine to what extent the
overall intervention effect changed when we excluded studies: at
severe or unclear risk of bias; that did not adjust for confounders;
from unpublished datasets; and that used odds ratios as effect
measures and were cross-sectional in design.
Summary of findings table
We assessed the overall quality of the evidence for the primary
outcome using the GRADE system for assessing the quality of ev-
idence (GRADE 2004; Guyatt 2008; Guyatt 2011; Schünemann
2006). GRADE takes into account issues not only related to in-
ternal validity but also to external validity, such as directness of
results. The ’Summary of findings’ tables present the main find-
ings of the review in a transparent and simple tabular format. In
particular, they provide key information concerning the quality of
evidence, the magnitude of effect of the interventions examined
and the sum of available data on the main outcomes.
TheGRADE systemuses the following criteria for assigning grades
of evidence.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Grading is decreased for the following reasons.
• Serious (−1) or very serious (−2) study limitation for risk
of bias.
• Serious (−1) or very serious (−2) inconsistency between
study results.
• Some (−1) or major (−2) uncertainty about directness (the
correspondence between the population, the intervention, or the
outcomes measured in the studies actually found and those
under consideration in our systematic review).
• Serious (−1) or very serious (−2) imprecision of the pooled
estimate(−1).
• Publication bias strongly suspected (−1).
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Grading is increased for observational studies for the following
reasons.
• Strong evidence of association - significant relative risk of
more than 2.0 (or less than 0.5) based on consistent evidence
from two or more observational studies, with no plausible
confounders (+1).
• Very strong evidence of association - significant relative risk
of more than 5.0 (or less than 0.2) based on direct evidence with
no major threats to validity (+2).
• Evidence of a dose response gradient (+1).
• All plausible confounders would have reduced the effect
(+1).
R E S U L T S
Description of studies
Results of the search
We identified 6720 unique records from database searching and
from reference lists of included studies and relevant reviews. We
excluded 6576 on the basis of title and abstract and retrieved 144
full-text articles for more detailed evaluation. We excluded 103 of
these (referring to 101 studies) after reading the full text because
they did not meet the inclusion criteria; we characterised 6 studies
as awaiting classification since they were written in Chinese or
German, and we were not able to translate.
We finally included 28 studies (31 references): 21 published and 7
unpublished reports that satisfied all criteria required for inclusion
in the review. See Figure 1.
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Figure 1. Study flow diagram.
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Twenty-one papers directly included measures of the impact of
exposure to either OST or NSP on HCV acquisition. In addition,
we identified 11 eligible prospective studies that measured HCV
incidence and contacted authors of these articles. Of these, we
obtained unpublished data from six cohort studies in Montreal,
Canada (Bruneau 2015 [pers comm]); Baltimore, USA (Mehta
2015 [pers comm]), SanFrancisco,USA (Page 2015 [pers comm]);
London, UK (Judd 2015 [pers comm]); Melbourne, Australia (
Aitken 2015 [pers comm]); and Sydney, Australia (Maher 2015);
plus one cross-sectional survey (Hope 2015 [pers comm]).
Included studies
See Characteristics of included studies.
In total we included 21 published studies (Craine 2009; Crofts
1997; Hagan 1995; Hagan 1999; Holtzman 2009; Hope 2011;
Lucidarme 2004; Nolan 2014, Palmateer 2014a ; Patrick 2001;
Rezza 1996; Roy 2007; Ruan 2007; Spittal 2012; Thiede 2000;
Thorpe 2002; Tsui 2014; Vallejo 2015; Van Beek 1998; Van
Den Berg 2007; White 2014), plus 7 unpublished studies (Aitken
2015 [pers comm]; Bruneau 2015 [pers comm]; Hope 2015 [pers
comm], Judd 2015 [pers comm]; Maher 2015 Mehta 2015 [pers
comm]; Page 2015 [pers comm]), comprising 1817HCV incident
infections and 8806.95 person-years of follow-up. HCV incidence
in the 28 studies ranged from 0.09 and 42 cases per 100 person-
years.
Design
Wedid not identify any randomised controlled trials.We included
2 case-control studies (Hagan 1995, Rezza 1996), 3 cross-sectional
studies (Hope 2011; Hope 2015 [pers comm]; Palmateer 2014a),
20 prospective cohort studies (Aitken 2015 [pers comm]; Bruneau
2015 [pers comm]; Craine 2009; Hagan 1999; Holtzman 2009;
Judd 2015 [pers comm]; Lucidarme 2004; Maher 2015; Mehta
2015 [pers comm]; Nolan 2014; Page 2015 [pers comm]; Patrick
2001; Ruan 2007; Spittal 2012; Thiede 2000; Thorpe 2002;
Tsui 2014; Vallejo 2015; Van Den Berg 2007; White 2014); 2
retrospective cohort studies (Crofts 1997; Van Beek 1998); and 1
serial cross-sectional survey (Roy 2007).
Duration of trials
For cohort studies the duration of follow-up ranged between 1
and 22 years. Included studies were published between 1995 and
2014.
Participants and setting
Twenty-five studies reported participants’ sex, and the mean pro-
portion of female participants was 32% (range 2.8% to 55.9%).
Across 14 studies, on average 40.7% (range 9.2% to 69.2%) of
participants had experience of recent or past homelessness, and
35% (range 18.2% to 90%) had experience of prison (12 studies).
The mean reported use of stimulants was 32.7% (range 0% to
75%, 19 studies) and amean of 50.5% (range 18.2% to 100%) re-
ported heroin use (13 studies). Across 14 studies a mean of 50.6%
of participants reported injecting daily (range 18.2% to 84%).
Most study participants were currently injecting at the time of
recruitment, with eligibility criteria for study participation stated
as: injection in the previous four weeks (Craine 2009; Hope 2011;
Hope 2015 [pers comm]; Judd 2015 [pers comm]; Nolan 2014;
Page 2015 [pers comm]; Patrick 2001; Spittal 2012; Thiede 2000;
Tsui 2014; Vallejo 2015), in the previous 3 months to 6 months
(Aitken 2015 [pers comm]; Bruneau 2015 [pers comm]; Hagan
1995;Maher 2015;Roy 2007;Ruan 2007;Thorpe 2002), or in the
previous 6 months to 12 months (Hagan 1999; Holtzman 2009;
Palmateer 2014a; White 2014). A few studies included PWID
who had injected at any time in the past (Lucidarme 2004, Mehta
2015 [pers comm]; Van Den Berg 2007), or they reported no
information on recency of injection (Crofts 1997; Rezza 1996;
Van Beek 1998).
Eight studies took place in the USA; five each in the UK, Canada
andAustralia; and one each in theNetherlands, France, Italy, Spain
and China.
Study size and method of recruitment
Sample size ranged from46 and 2788. Themethod of recruitment
primarily involved street outreach, in 13 studies (Craine 2009;
Crofts 1997; Hagan 1995; Hagan 1999; Lucidarme 2004; Page
2015 [pers comm]; Palmateer 2014a; Rezza 1996; Roy 2007;
Thiede 2000; Tsui 2014; Van Beek 1998; Van Den Berg 2007);
respondent-driven sampling, in 3 studies (Holtzman 2009; Hope
2011; Hope 2015 [pers comm]); and service attenders (both low-
threshold community services and drug treatment), in 12 studies
(Aitken 2015 [pers comm]; Bruneau 2015 [pers comm]; Judd
2015 [pers comm];Maher 2015;Mehta 2015 [pers comm];Nolan
2014; Patrick 2001; Ruan 2007; Spittal 2012; Thorpe 2002;
Vallejo 2015; White 2014). Most studies drew on a combination
of recruitment methods.
Types of interventions
Twenty-one of the included studies assessed the impact of OST
(Craine 2009; Crofts 1997; Lucidarme 2004; Nolan 2014;
Palmateer 2014a; Rezza 1996; Ruan 2007; Spittal 2012; Thiede
2000; Tsui 2014; Vallejo 2015; Van Beek 1998; Van Den
Berg 2007; White 2014), including seven unpublished estimates
(Aitken 2015 [pers comm]; Bruneau 2015 [pers comm]; Hope
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2015 [pers comm]; Judd 2015 [pers comm]; Maher 2015; Mehta
2015 [pers comm]; Page 2015 [pers comm]).
Current use of OST was defined as: reporting use of prescribed
methadone or buprenorphine within the previous six months (yes
or no) (Bruneau 2015 [pers comm]; Maher 2015; Nolan 2014;
Rezza 1996; White 2014); use for more than six months (Judd
2015 [pers comm]), use of methadone or buprenorphine at the
time of survey (Craine 2009; Hope 2015 [pers comm]; Mehta
2015 [pers comm]; Palmateer 2014a; Spittal 2012), or continu-
ous use of methadone throughout follow-up period (Crofts 1997;
Lucidarme 2004; Thiede 2000). Van Den Berg 2007 defined con-
tinuous use as daily use of methadone (any dosage) in the previous
six months, while Aitken 2015 [pers comm] defined it as in the
previous one month. Tsui 2014 used a three-month time frame to
measure use of OST (methadone or buprenorphine).
Seventeen studies assessed the impact ofNSP (Hagan 1995;Hagan
1999; Holtzman 2009; Hope 2011; Palmateer 2014a; Patrick
2001; Roy 2007; Thorpe 2002; Vallejo 2015; VanDenBerg 2007;
White 2014), including five unpublished sources (Bruneau 2015
[pers comm];Hope 2015 [pers comm];Maher 2015;Mehta 2015
[pers comm]; Page 2015 [pers comm]).
Bruneau 2015 [pers comm] defined high NSP coverage as obtain-
ing 100% of needles/syringes from a safe source (receiving one
clean needle for every injection), Hope 2011, Hope 2015 [pers
comm]and Van Den Berg 2007 defined it as reporting ≥100%
of injections using clean needles/syringes (receiving one or more
clean needle for every injection), and Palmateer 2014a defined it
as reporting ≥200% of injections with clean syringes (receiving
more than two clean needles for every injection). Other measures
of high coverage were defined as regular attendance at least once
per week at an NSP in Patrick 2001 or obtaining most needles/
syringes from an NSP in the last six months (Hagan 1999).
Low-level NSP coverage was defined as ever having used an NSP
(Hagan 1995), using NSPs in the previous one to six months
(Holtzman 2009; Maher 2015; Mehta 2015 [pers comm]; Page
2015 [pers comm]; Roy 2007; Thorpe 2002; White 2014), or
having less than 100% of injections covered by a clean needle/
syringe in the last six months (Hope 2011; Van Den Berg 2007).
Four studies assessed the impact of combined NSP with OST
(Hope 2011; Palmateer 2014a; Van Den Berg 2007), including
one unpublisheddata source (Bruneau 2015 [pers comm]). Studies
defined combined use of NSP plus OST in two ways: high NSP
coverage plus current use of OST (Bruneau 2015 [pers comm];
Hope 2011; Palmateer 2014a; Van Den Berg 2007), and OST use
plus low NSP coverage (Hope 2011; Palmateer 2014a; Van Den
Berg 2007). One study looked at the impact of uptake of injecting
paraphernalia (defined as spoons and filters) alone, with needles/
syringes and in combination with OST (Palmateer 2014a).
Excluded studies
See Characteristics of excluded studies.
We excluded 101 studies (104 articles). Grounds for exclusion
were: no outcome of interest assessed (43 studies); no intervention
of interest (32 studies); no comparison of interest (all participants
onOST, 9 studies); no outcome and no intervention of interest (11
studies); no outcome and no comparison of interest (4 studies);
and editorial or overview (2 studies).
Risk of bias in included studies
Bias due to baseline confounding
We judged 12 studies to be at moderate risk of bias due to con-
founding because they adjusted for critical confounders (duration
of injecting or age, and frequency of injecting) and used a suitable
analysis method (e.g. adjusted for time-varying confounding if ap-
propriate) (Bruneau 2015 [pers comm];Hagan 1999;Hope 2011;
Hope 2015 [pers comm]; Judd 2015 [pers comm]; Lucidarme
2004; Maher 2015; Mehta 2015 [pers comm]; Page 2015 [pers
comm]; Thiede 2000; Tsui 2014; White 2014). We judged 12
to be at serious risk because confounding was insufficiently ad-
dressed in the analyses (Craine 2009; Hagan 1995; Holtzman
2009; Nolan 2014; Palmateer 2014a; Patrick 2001; Rezza 1996;
Roy 2007; Spittal 2012; Thorpe 2002; Vallejo 2015; Van Den
Berg 2007). The four studies we assessed as being at critical risk
did not make any adjustment for confounding (Aitken 2015 [pers
comm]; Crofts 1997; Ruan 2007; Van Beek 1998).
Bias in the selection of participants into the study
We deemed five studies to be at moderate risk of bias because start
of follow-up and start of intervention coincided for all or most
subjects (Hope 2011; Hope 2015 [pers comm]; Patrick 2001;
Thiede 2000; Tsui 2014). We judged three studies to be at critical
risk of bias because selection into the study was strongly related to
intervention and outcome (Aitken 2015 [pers comm]; Judd 2015
[pers comm]; Ruan 2007). We considered the remaining studies
to be at serious risk of selection bias, largely because participants
may have already been exposed to the intervention prior to the
start of the study. For two studies (Mehta 2015 [pers comm]; Page
2015 [pers comm]), we did not have enough information to make
a judgment.
Bias in measurement of the intervention
We judged five studies to be at low risk of bias because intervention
status was well defined and based solely on information collected
at the time of intervention (Crofts 1997; Hagan 1999; Thiede
2000; Tsui 2014; Vallejo 2015). We deemed seven studies to be at
moderate risk because some aspects of the assignments of interven-
tion status were determined retrospectively (Bruneau 2015 [pers
comm]; Holtzman 2009; Nolan 2014; Palmateer 2014a; Spittal
2012; Van Den Berg 2007; White 2014). We considered Judd
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2015 [pers comm] to be at critical risk of bias because there was
considerable risk of misclassification of intervention status. We
judged the remaining studies to be at serious risk of selection bias
mainly because intervention status was not well defined. For two
studies (Mehta 2015 [pers comm]; Page 2015 [pers comm]), we
did not have enough information to make a judgment.
Blinding
Departures from intended interventions: none of the studies
provided information about co-interventions received by partici-
pants or changes in treatment, so we coded departures from in-
tended interventions as ’no information’ for all studies.
Measurement of outcomes: we deemed all but one study to be at
low risk of bias in relation to measurement of the outcome since
HCV seroconversion was laboratory-confirmed, and testing was
carried out at pre-defined time points, with no apparent differences
between intervention groups. InCrofts 1997, the risk was serious
because there may have been differential testing (for participants
not on methadone, the need for HCV testing was determined
according to the clinician’s judgment).
Incomplete outcome data
Six studies were at a low risk of bias because data were reasonably
complete (Hagan 1995; Hagan 1999; Hope 2011; Nolan 2014;
Spittal 2012; Thiede 2000), and two studies were at moderate
risk of bias because there were no substantial differences in the
proportions of missing data or in reasons for missing data across
intervention groups (Thorpe 2002; Tsui 2014). The eight stud-
ies at serious risk (Craine 2009; Crofts 1997; Lucidarme 2004;
Palmateer 2014a; Patrick 2001; Ruan 2007; Vallejo 2015; Van
Den Berg 2007), and the five at critical risk (Aitken 2015 [pers
comm]; Judd 2015 [pers comm]; Rezza 1996; Roy 2007; Van
Beek 1998), had substantial differences in either the proportions
of missing participants or the reasons for missing data across in-
terventions, and investigators did not adjust for these differences
in the analyses. Seven studies provided insufficient information
about missing data or the potential for data to bemissing (Bruneau
2015 [pers comm]; Holtzman 2009; Hope 2015 [pers comm];
Maher 2015; Mehta 2015 [pers comm]; Page 2015 [pers comm];
White 2014).
Selective reporting
We judged all studies to be at low risk for selective reporting as
the measure of the outcome of interest was clearly defined and
internally consistent. For one study (Aitken 2015 [pers comm]),
there was insufficient information for assessing reporting bias.
Overall risk of bias
We judged only 2 studies to be at moderate overall risk of bias
(Thiede 2000; Tsui 2014), while 17 were at serious overall risk
(Bruneau 2015 [pers comm]; Craine 2009; Hagan 1995; Hagan
1999; Holtzman 2009; Hope 2011; Lucidarme 2004; Maher
2015; Nolan 2014; Palmateer 2014a; Patrick 2001; Spittal 2012;
Thorpe 2002; Vallejo 2015; White 2014), and 7 were at critical
risk (Aitken 2015 [pers comm]; Crofts 1997; Judd 2015 [pers
comm]; Rezza 1996; Roy 2007; Ruan 2007; Van Beek 1998).
For two studies, we did not have enough information to make a
judgment (Mehta 2015 [pers comm]; Page 2015 [pers comm]).
This is summarised in Table 1.
Effects of interventions
See: Summary of findings for the main comparison Current
OST versus no OST for people who inject drugs; Summary of
findings 2 High NSP coverage versus no/low NSP coverage for
people who inject drugs; Summary of findings 3CombinedOST
and high NSP versus no OST and low/no NSP for people who
inject drugs
1. Current use of OST versus no current OST
Of the 20 studies that assessed the impact of OST on HCV in-
cidence, we pooled data from 17 studies that measured current
OST (Craine 2009; Crofts 1997; Lucidarme 2004; Nolan 2014;
Palmateer 2014a; Rezza 1996; Spittal 2012; Thiede 2000; Tsui
2014; Vallejo 2015; Van Den Berg 2007; White 2014), including
five unpublished estimates (Aitken 2015 [pers comm]; Bruneau
2015 [pers comm]; Hope 2015 [pers comm]; Judd 2015 [pers
comm]; Maher 2015).
Fourteen of the included studies were longitudinal studies, one
used a case-control study design (Rezza 1996), and two were cross-
sectional surveys (Hope 2015 [pers comm]; Palmateer 2014a).
A total of 1148 HCV incident cases were included over 6553.1
person-years of follow-up.
The primary analyses were focused on twelve studies present-
ing adjusted estimates. These analyses included the following ef-
fect measures: hazard ratios in six studies (Bruneau 2015 [pers
comm]; Lucidarme 2004; Maher 2015; Tsui 2014; White 2014),
odds ratios in five studies (Judd 2015 [pers comm]; Nolan 2014;
Palmateer 2014a; Rezza 1996; Thiede 2000), and incident rate
ratio in two studies (Craine 2009; Mehta 2015 [pers comm]).
Adjusted estimates controlled for potential confounding effects
of the following factors: duration and frequency of injection
(Bruneau 2015 [pers comm]; Judd 2015 [pers comm]); area of
residence, homelessness, sharing injecting equipment or needles
(Craine 2009); sex, geographical region, use of condoms, injec-
tion of cocaine, duration of injection, sharing injecting equipment
(Lucidarme 2004); duration of injection, frequency of injection
and age of whole cohort (Mehta 2015 [pers comm]); unstable
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housing, cocaine, heroin or methamphetamine injection, cohort
of recruitment, year of recruitment, follow-up time (Nolan 2014);
survey year, homelessness, stimulant injection, duration of injec-
tion (Palmateer 2014a); sex, age, duration of drug use, injection
of cocaine (Rezza 1996); age, duration of injection, sex, ethnic-
ity, homelessness or prison in the last 3 months (Tsui 2014); sex,
ethnicity, age, frequency of injecting and sharing needles/syringes
(White 2014); and injected at follow-up, pooled money to buy
drugs, injected with used needles and backloading (removing the
plunger from a syringe and filling it with drug solution from an-
other needle/syringe) (Thiede 2000).
Random-effects meta-analysis of multivariable estimates showed
that opioid substitution therapy was associated with a 50% re-
duction in the risk of HCV infection (RR 0.50 95% CI 0.40 to
0.63) with little heterogeneity between 12 studies involving 6361
participants (I2 = 0%, P = 0.89, Tau2 = 0.00; Analysis 1.1; Figure
2).
Figure 2. Forest plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted
analyses by region.
Sensitivity analysis
The intervention effect strengthened when we excluded estimates
from four unpublished data sources (Bruneau 2015 [pers comm];
Judd 2015 [pers comm];Maher 2015;Mehta 2015 [pers comm]):
RR 0.42 (95%CI 0.31 to0.58; Analysis 2.1; I2 = 0%, Tau2 = 0.00,
8 studies, N = 5235).
This effect was maintained when the analysis was limited to ex-
cluding Judd 2015 [pers comm] and Rezza 1996, judged to be at
critical risk of bias, and Mehta 2015 [pers comm], which reported
insufficient information to give an overall risk of bias assessment
(RR 0.51, 95% CI 0.40 to 0.64; Analysis 3.1 I2 = 0%, Tau2 =
0.00). The intervention effect was also unchanged when the analy-
sis excluded Palmateer 2014a and Rezza 1996, two cross-sectional
studies that reported baseline measures of effect only (RR 0.51,
95% CI 0.40 to 0.65; Analysis 4.1; I2 = 0.0%, Tau2 = 0.00, 10
studies, N = 3367).
Random-effects meta-analysis of 16 studies that presented unad-
justed estimates shows that current OST was associated with a
43% reduction in the risk of HCV acquisition (RR 0.57, 95%
CI 0.45 to 0.73; Analysis 5.1; 16 studies, N = 10,647), with only
moderate evidence of heterogeneity between studies (I2 = 32.4%,
P = 0.09, Tau2 = 0.08).
Meta-regression
Based on univariable meta-regression of unadjusted estimates, we
found no evidence that effectiveness varied by other covariates
15Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
including geographical location (Analysis 1.1) or study design (
Analysis 1.2). We did find evidence of differential impact in the
proportion of female participants in the sample. With each 10%
increase of female participants in sample, the effect of intervention
exposure was reduced (ratio of rate ratios = 1.59, 95% CI 1.13 to
2.29; Table 2).
History of OST
Three studies published unadjusted estimates of lifetime use of
OST versus never using OST, comprising 115 HCV cases over
511.6 person-years from three prospective cohorts (Ruan 2007;
Vallejo 2015; Van Beek 1998). One study did not define the time
frame, so we coded it as lifetime experience of OST (Vallejo 2015).
Three studies published unadjusted estimates of interrupted OST
use versus no interruption of use (Crofts 1997; Nolan 2014;
Thiede 2000). Two of these studies were prospective cohorts and
one retrospective; they included a total of 200 HCV cases over
2273.8 person-years. Interrupted OST use was defined either as
use of MMT at baseline but not at follow-up (Nolan 2014), or
leavingMMT at least once during follow-up (Crofts 1997; Thiede
2000).
One prospective cohort study comprising 149 HCV cases over
680 person-years examined OST for detoxification (Tsui 2014),
and two studies measured high (60mg or more) or low dosage (less
than 60 mg) methadone in the last 6 months (Bruneau 2015 [pers
comm]; Van Den Berg 2007). Both these studies were prospective
cohorts and included 148 HCV cases over 598.6 person-years.
Random-effectsmeta-analysis showed a very weak protective effect
for lifetime (RR 0.81, 95% CI 0.52 to 1.27, I2 = 0%, Tau2 = 0.00,
3 studies, N = 385) or interrupted use of OST (RR 0.80, 95% CI
0.57 to 1.10, I2 = 86.1%, Tau2 = 0.05, 3 studies, N = 1157). The
one study measuring the impact of OST used for detoxification
was not associated with reduced HCV risk acquisition (RR 1.45,
95% CI 0.79 to 2.66, Tau2 = 0.00, N = 552). In the two studies
that categorised OST dosage and HCV acquisition, we found a
moderate association for those exposed to high dosage OST (RR
0.52, 95% CI 0.29 to 0.94, I2 = 27.2%, Tau2 = 0.05, N = 453)
and a very weak association for those exposed to low dosage OST
(RR 0.85, 95% CI 0.44 to 1.65; Analysis 1.3; I2 = 61.2%, Tau2
= 0.14, N = 453).
Publication bias
A funnel plot of 13 estimates (12 studies) suggested no evidence
of publication bias in studies of current OST exposure (Figure 3).
Figure 3. Funnel plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted
analyses by region.
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2. Needle syringe programmes versus lower or no
NSP coverage
Of the 15 studies that reported measures of NSP exposure and
HCV incidence, comparison groups consisted of NSP non-atten-
dance (Hagan 1995; Hagan 1999; Holtzman 2009; Maher 2015;
Mehta 2015 [pers comm]; Page 2015 [pers comm]; Patrick 2001;
Roy 2007; Thorpe 2002; Van Den Berg 2007), lower coverage of
injections covered by a clean needle/syringe (Hope 2011; Hope
2015 [pers comm]; Palmateer 2014a; Van Den Berg 2007), and
non-attendance at NSP and not using a safe source for obtaining
needles/syringes (Bruneau 2015 [pers comm]).
2.1 High coverage versus non-attendance or lower coverage
Five studies reported adjusted measures of high NSP coverage
and HCV incidence (Hagan 1999; Hope 2011; Palmateer 2014a;
Patrick 2001), including one unpublished dataset (Bruneau 2015
[pers comm]). Three were prospective cohorts (Bruneau 2015
[pers comm], Hagan 1999, Patrick 2001), and two were cross-
sectional surveys (Hope 2011; Palmateer 2014a), comprising 407
HCV cases over 1644 person-years. Effect measures used in these
studies included: hazard ratios in two studies (Bruneau 2015 [pers
comm], Patrick 2001), odds ratios in two studies (Hope 2011;
Palmateer 2014a), and risk ratio in one study (Hagan 1999).
Random-effects meta-analysis showed weak evidence that high
coverage NSP was not associated with reduced risk of HCV in-
fection (RR 0.79, 95% CI 0.39 to 1.61) derived from 5 studies
with 3530 participants and high heterogeneity between studies (I
2 =77%, P = 0.002, Tau2=0.44; Figure 4; Analysis 6.1).
Figure 4. Forest plot of comparison: 2 High NSP coverage versus no/low NSP coverage, outcome: 2.1 HCV
incidence adjusted analyses by region.
Sensitivity analyses
Evidence of any intervention effect became weaker after excluding
the unpublished dataset of Bruneau 2015 [pers comm] (RR 0.77,
95% CI 0.28 to 2.13; Analysis 7.1; Tau2 = 0.81, 4 studies, N =
3245). We did not rate any studies as being at critical risk of bias.
The intervention effect disappeared whenwe excludedHope 2011
and Palmateer 2014a, two cross-sectional studies (RR 1.25, 95%
CI 0.63 to 2.46; Analysis 8.1; I2 = 77.0%, Tau2 = 0.27, 3 studies,
N = 627).
Random-effects meta-analysis of seven studies that presented un-
adjusted estimates show that the weak intervention effect was un-
changed (RR 0.78, 95% CI 0.39 to 1.55; Analysis 9.1; I2 = 79%,
Tau2 = 0.72).
Meta-regression
Based on univariable meta-regression analyses, we found evidence
that the effectiveness of high NSP coverage varied according to
geographical region. High NSP coverage was associated with a
76% reduction in HCV acquisition risk (RR 0.24, 95% CI 0.09
to 0.62), with less heterogeneity between two European studies in
2903 participants (I2 = 0%, P = 0.66). There was no evidence of
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an intervention effect from studies in North America (RR 1.25,
95% CI 0.63 to 2.46; Analysis 6.1; I2 = 77%, 3 studies, N = 627;
Figure 4). There was some evidence of a differential impact in the
meta-regression analysis (ratio of rate ratios 3.73, 95% CI 0.95 to
14.7, P = 0.057; Table 3). Although univariable meta-regression
analysis suggested some association between high coverage of NSP
and study design (ratio of rate ratios 3.5, 95% CI 0.78 to 15.8, P
= 0.087), this was reduced when adjusted by geographical region
(ratio of rate ratios 1.7, 95%CI 0.18 to 16.9, P = 0.58), suggesting
any association is confounded by region (Analysis 6.2; Table 3).
2.2 Low-level coverage of NSP versus no NSP coverage
Six studies involving 2763 participants reported adjustedmeasures
of low-level NSP coverage and HCV incidence (Hagan 1995;
Hagan 1999; Holtzman 2009; Maher 2015; Mehta 2015 [pers
comm]; Page 2015 [pers comm]). Random-effects meta-analysis
showed no evidence of an intervention effect of low NSP coverage
on HCV risk acquisition, with moderate levels of heterogeneity
(RR 1.43, 95% CI 0.82 to 2.49; Analysis 10.1; I2 = 69.1%, Tau2
= 0.272).
Sensitivity analysis
Ten studies reported unadjusted measures of low-level NSP cover-
age and HCV incidence. Eight were prospective cohorts (Hagan
1999; Holtzman 2009; Maher 2015; Mehta 2015 [pers comm];
Page 2015 [pers comm];Thorpe 2002;VanDenBerg 2007;White
2014), and one was a case-control study (Hagan 1995). We ex-
cluded another prospective cohort study since it did not report
95% confidence intervals around the effect estimate, nor the num-
ber of new HCV cases in intervention and comparison groups
required to estimate it (Roy 2007). A total of 531 cases were in-
cluded in the analyses over 1617 person-years. Random-effects
meta-analysis showed no evidence of an intervention effect for low
NSP coverage on HCV risk acquisition, with moderate levels of
heterogeneity (RR 1.41 95% CI 0.95 to 2.09; Analysis 11.1; I2 =
62.3%, Tau2 = 0.19, 9 studies, N = 3242).
3. Combined needle syringe programmes plus opioid
substitution therapy versus low or no NSP coverage
and no OST
Four studies reported combined exposure to both NSPs and OST
(Hope 2011; Palmateer 2014a; VanDenBerg 2007) including one
unpublished dataset (Bruneau 2015 [pers comm]). The primary
analyses focused on three studies presenting adjusted estimates
(Bruneau 2015 [pers comm]; Palmateer 2014a; Van Den Berg
2007). A total of 511 HCV incident cases were included in the
analysis examining high NSP coverage, and 437 cases for lowNSP
coverage. Only one study reported the number of person-years
(Van Den Berg 2007).
Random-effects meta-analysis showed that combined use of OST
plus high coverage of NSP was associated with a 76% risk reduc-
tion in HCV acquisition (RR 0.26, 95% CI 0.07 to 0.89; Analysis
12.1; I2 = 80%, Tau2 = 0.94; 3 studies, N = 3241; Figure 5). The
effect of exposure to OST and low coverage of NSP was weaker
(RR 0.87, 95% CI 0.44 to 1.68; Analysis 12.1; I2 = 36.0%, Tau2
= 0.09; 2 studies, N = 2956 participants; Figure 5).
Figure 5. Forest plot of comparison: 4 Combined OST and high/low NSP versus no OST and low/no NSP,
outcome: 4.1 HCV incidence adjusted analyses.
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Sensitivity analysis
Four studies reported unadjusted estimates of combined expo-
sure to both NSPs and OST (Hope 2011; Palmateer 2014a; Van
Den Berg 2007) including one unpublished dataset (Bruneau
2015 [pers comm]). Twowere cross-sectional surveys (Hope 2011;
Palmateer 2014a), and two were prospective cohorts (Bruneau
2015 [pers comm]; Van Den Berg 2007). The analysis examining
high NSP coverage included a total of 518 HCV incident cases,
and the analysis for low NSP coverage, 449 cases. Random-effects
meta-analysis showed that combined use of OST plus high cov-
erage of NSP was associated with a 71% risk reduction in HCV
acquisition (RR 0.29, 95% CI 0.13 to 0.65, I2 = 64.4%, Tau2 =
0.07, 4 studies, N = 3356). The effect of exposure to OST and
low coverage of NSP was weaker (RR 0.76, 95% CI 0.44 to 1.33;
Analysis 12.2; I2 = 29.6%, Tau2 = 0.4, 3 studies, N = 2956).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High NSP coverage versus no/ low NSP coverage
Patient or population: people who inject drugs
Settings: outpat ients
Intervention: high NSP coverage versus no/ low NSP coverage
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No/ low NSP coverage High NSP coverage
HCV incidence adjusted
analyses
number of HCV seroconver-
sion
Follow-up: mean 269 per-
son-years
- - RR: 0.79 (0.39 to 1.61) 3530
(5 studies)
⊕©©©
Very lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NSP: needle syringe programmes; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level due to serious overall risk of bias in all the studies.
bDowngraded one level due to signif icant heterogeneity: I2: 77%.
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Combined OST and highNSP versus no OST and low/no NSP
Patient or population: people who inject drugs
Settings: outpat ients
Intervention: Combined OST and high/ low NSP versus no OST and low/ no NSP
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No OST and low/no NSP Combined OST and high
NSP
HCV incidence adjusted
analyses
number of HCV seroconver-
sions
Follow-up: mean 356 per-
son-years
- - RR: 0.26 (0.07 to 0.89) 3241
(3 studies)
⊕⊕⊕©
Lowa,b
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; NSP: needle syringe programmes; OST : opioid subst itut ion therapy; RR: Risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level due to serious overall risk of bias in all studies.
bUpgraded one level due to very large magnitude of the ef fect: RR: 0.26.
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D I S C U S S I O N
Summary of main results
Opioid substitution treatment (OST)
Primarymeta-analysis of 12 observational studies adjusting for key
confounders and enrolling 6361 anti-HCV negative participants
showed that current use of opioid substitution therapy reduced
the risk of HCV acquisition by 50% (95% CI 37% to 60%) com-
pared to no current OST use. The intervention effect is strong,
but the evidence is considered as low quality because it was derived
from observational studies with serious risk of bias. Nonetheless,
the findings were robust to sensitivity analyses excluding studies
judged to be at critical risk of bias; studies drawing on unpublished
data; case-control and cross-sectional studies only reporting base-
line data; and studies reporting only unadjusted estimates. There
was also no evidence of publication bias.
Meta-regression analysis suggested evidence of a differential im-
pact of OST by the proportion of female participants in the sam-
ple. With each 10% increase in female participants, the effect of
intervention exposure was reduced by 59%. None of the included
studies reported uptake of OST by sex to understand whether
individual-level analyses supported this evidence of a differential
intervention effect. Other epidemiological evidence suggests that
women are at increased risk of acquiring hepatitis C compared
to men (Esmaeli 2016; Iversen 2015; Miller 2004; Tracy 2014).
This increased risk has been linked to having a sexual partner who
also injects, being initiated into injection by a sexual partner be-
ing injected by others or consistently injecting after other people
with used needles/syringes (Bourgois 2004; Iversen 2015). Our
findings suggest that women may have poorer access to OST than
men, and this is supported by recent review work that suggests
services do not take into account gender-specific needs and are
often tailored towards men (Iversen 2015).
Only a few studies reported other types of exposure to OST: three
studies reported past exposure to OST; three reported interrupted
OSTuse; one study measuredOSTuse for detoxification; and two
studies measured high dosage (more than 60 mg) or low dosage
(1 to 59 mg) of methadone for daily use. Among these exposures,
only high dosage of OST was associated with a reduction in risk
of HCV acquisition.
Needle and syringe programmes (NSP)
Meta-analysis of five observational studies pooling adjusted esti-
mates from 3530 anti-HCV negative participants show low-qual-
ity evidence that high NSP exposure does not reduce the risk of
HCV acquisition. Selected sensitivity analyses increased the un-
certainty around the intervention effect.However,meta-regression
showed a strong association between intervention effect and re-
gion. After removing studies from North America, heterogeneity
was reduced, and high NSP coverage in Europe was associated
with a 76% (95% CI 38% to 91%) reduction in HCV acquisition
risk (RR 0.24, 95% CI 0.09 to 0.62).
Combined NSP and OST
Primary meta-analysis of three studies involving 3241 anti-HCV
negative participants and adjusting for confounders suggested a
strong intervention effect for combined high coverage of NSP and
OST, reducing the risk of HCV acquisition by 74% (95%CI 11%
to 93%) compared to no OST and low/no coverage with NSP.
The evidence is considered low quality because it was derived from
observational studies with serious risk of bias, and the few studies
identified precluded sensitivity analyses. Evidence for the combi-
nation of low coverage of NSP and OST was weaker. There were
fewer studies with information on both OST and NSP coverage,
and the studies represented a subset of people on OST (i.e. par-
ticipants who continue to inject drugs while on OST), with those
on low coverage NSP receiving an insufficient number of sterile
syringes per average frequency of injecting.
Overall completeness and applicability of
evidence
We found no historical RCT evidence that assessed the impact
of NSP or OST on HCV transmission. There was a larger body
of observational evidence that examined the effectiveness of NSPs
and OST in reducing HCV acquisition among PWID - but the
evidence was concentrated in few geographical areas and regions.
Most evidence came from North America and Western Europe.
Only one study was identified from China (Ruan 2007), and we
did not find any studies from Eastern Europe or Southeast Asia,
where there are the largest populations of PWID and hence the
highest burden of disease associated with bloodborne infections
(Gower 2014; Mathers 2008; Platt 2016).
Quality of the evidence
We assessed many studies included in the review as being at severe
risk of bias - with only two being at moderate overall risk and
seven at critical risk. Only a few studies reported the interven-
tion effect of high NSP coverage adjusting for confounders (5/7),
which limited the sensitivity analyses that we could conduct. The
GRADE assessment criteria takes RCTs to be the gold standard
study design, and observational studies are by default rated as low
quality, so the assessment begins low, despite this being the only
evidence available for examining this question. While certainty in
the results may be undermined by the lack of experimental stud-
ies, the intervention effect estimates for current use of OST were
consistent and robust across sensitivity analyses, and the size of
effect is high. GRADE guidelines also state that judgments about
the overall quality of evidence require information beyond the re-
sults of the review (GRADE 2004). Considering the wealth of
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supporting evidence showing the beneficial effects of OST in re-
ducing injecting harms, HIV and bacterial infections, and in im-
proving access to services, we are confident that the assessment
is fair (Hagan 2011; MacArthur 2012; Palmateer 2010; Turner
2011; Vickerman 2012; Vickerman 2014).
Potential biases in the review process
A potential bias in the review was the heterogeneity across the
studies in the use of multiple effect measures. Effect measures were
converted into risk ratios in the meta-analysis, but this may have
introduced bias into our findings since we had to assume that risk
ratios approximated odds ratios, which may be inappropriate for
some sites given the high incidence of HCV seroconversion. We
removed cross-sectional study designs that identified serological
markers of incidence infection as part of our sensitivity analysis.
Effect estimates remained the same for current use of OST versus
no intervention, but not for high coverage of NSPs. Nonetheless,
most studies recruited people who inject drugs currently or re-
cently, which may not be representative of all PWID exposed to
OST and may lead to an underestimation of the effect of OST
on HCV transmission. For example, in the Amsterdam cohort,
people who reported being on OST and having ceased injecting
had a lower risk of HCV transmssion (Van Den Berg 2007). An-
other potential bias is the use in three studies of HCVRNA testing
for anti-HCV negative samples to obtain an estimate of incidence
(Hope 2011; Hope 2015 [pers comm]; Palmateer 2014a). Poten-
tial limitations of this method include delayed or weak antibody
response due to a compromised immune system and uncertainty
around the incidence window period (Hope 2010). All included
studies estimating incidence from RNA samples used the same
formula and comparable window periods. We didn’t include any
studies that used avidity testing, minimising any further misclas-
sification of outcomes that that approach brings through the un-
certainty in window periods.
Agreements and disagreements with other
studies or reviews
Our review corroborates and underpins an earlier review that
showed consistent and large effects of NSP and OST on inject-
ing risk behaviours associated with bloodborne virus transmission
(Gowing 2011). Two recent reviews focused on the effectiveness
of OST and NSPs in reducing HCV incidence. Our findings cor-
roborate the most recent pooled analysis, which suggested that re-
ceiving OST and high coverage of NSP can each reduce HCV in-
fection risk alone but have a greater effect in combination (Turner
2011). The estimate for association between exposure to NSP and
HCV incidence was weak in the pooled analysis and was focused
on studies from theUK only. Findings from our subgroup analysis
suggested a stronger effect of high NSP coverage in Europe. This
finding builds directly on the Turner 2011 analysis through the
addition to the meta-analysis of the earlier Van Den Berg 2007
along with more recent studies and datasets (Hope 2015 [pers
comm]), and it strengthens the efficacy estimate for Europe sug-
gesting reduced risk of HCV acquisition (RR 0.24 95% CI 0.09
to 0.62). We found no effect of high NSP coverage when pooling
estimates from North America and greater heterogeneity across
the studies. This corroborates findings from another review that
found increased risk of seroconversion associated with NSP atten-
dance that relied on evidence predominantly fromNorth America
(Hagan 2011).
The lack of evidence for NSPs from studies in North America can
be attributed to a mixture of confounding, differences in inject-
ing patterns, potential selection bias and misclassification of expo-
sure. People who attend NSPs regularly also report greater inject-
ing risk behaviours, and any positive association between HCV
transmission and NSP attendance disappears after adjustment for
injecting risk. The effect of this residual confounding has been
demonstrated in further analyses of a cohort of PWID in Van-
couver, which demonstrated that higher HIV seroconversion rates
observed among daily NSP attenders were associated with high-
risk behaviours of attenders (including regular cocaine injection,
sex work involvement and homelessness) rather than use of the
NSP (Wood 2007). Likewise, a study in Seattle showed that peo-
ple who were homeless or who injected with used needle/syringes
were more likely to become new NSP users (Hagan 2000). The
higher proportion of stimulant injecting in North America also
means that the additional protective effect of OST is absent, which
may contribute to the impact of NSP on HCV risk in European
studies. Potential selection bias may occur since samples of cohort
studies are to some degree self-selected. Particularly when partici-
pants are lost to follow-up over time, they may be inherently dif-
ferent in terms of demographic characteristics and risk behaviours
that can influence the outcome. Misclassification of exposure may
also occur since it is difficult to make a clear distinction between
exposed and unexposed groups, and unexposed populations may
have access to clean needles/syringes through other sources than
NSPs. The European studies consistently used measures of NSP
exposure through coverage of injections by clean needles/syringes,
whereas the North American studies drew on varied definitions of
NSP use that focused on frequency of attendance at NSPs. Com-
parability in measurement of intervention exposure is reflected in
the higher heterogeneity observed among studies measuring ex-
posure to NSP (I2 = 77%, P = 0.002) compared to OST expo-
sure (I2 = 0%, P = 0.89). This is particularly relevant in relation
to measures of intervention exposure that focus on frequency of
attendance at an NSP rather than a measure of injections covered
by clean needle/syringes, and further explains the lack of effect be-
tween high NSP coverage and HCV incidence observed in North
America. It is also possible that the lack of effect of NSPs on HCV
transmission observed inNorth America is due to less frequent use
of NSPs. Previous evidence has shown that lack of federal funding
for NSPs in the USAhas resulted in lower coverage among PWID,
and this has been associated with higher HIV incidence than in
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other countries with higher NSP coverage (Wiessing 2009).
Findings also corroborate two recent systematic reviews that mea-
sured the impact of NSPs and OST on HIV transmission. These
previous analyses of 12 observational studies estimated a moderate
effect of NSPs on reducing HIV transmission by 48% (95% CI
3% to 72%) and strong evidence forOST reducingHIV transmis-
sion by 54% (95% CI 33% to 68%) (Aspinall 2014; MacArthur
2012).
A previous review of reviews from 2010 concluded that there was
insufficient evidence to assess the effectiveness of NSPs in reduc-
ing HCV incidence. This ’meta’ review synthesised findings from
four primary reviews, three of which focused primarily on HIV
as an outcome, missing much of the relevant data, and the fourth
predominantly relied on weaker study designs (Palmateer 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Opioid substitution treatment (OST) reduces the risk of HCV
acquisition in PWID. The evidence for the effectiveness of high
coverage needle syringe programmes (NSP)wasmoremixed - with
evidence from studies in Europe suggesting that NSP reduceHCV
transmission, but not in theUSA, probably due tomisclassification
of intervention exposure, selection bias of study participants and
unmeasured bias. The intervention effect is strengthened with the
combination of OST and high coverage NSP. The World Health
Organization (WHO), the Joint United Nations Programme on
HIV/AIDS, the United Nations Office on Drugs and Crime, the
European Centre for Disease Prevention and Control, and the
European Monitoring Centre for Drugs and Drug Addiction all
recommend OST and NSPs as key interventions for preventing
drug-related harm, including HCV transmission. Yet OST is not
widely implemented in many countries, prohibited in the Russian
Federation and often restricted by age or duration of dependency
prior to treatment entry (Mathers 2012).
Our findings show the need to remove restrictions on the con-
current use of both NSP and OST to maximise reduction
in HCV transmission. Distribution of needles/syringes through
NSPs needs to be maintained alongside provision of OST. NSP
and OST services need to recognise the role of gender and develop
appropriate policies and practice to encourage women to use ser-
vices addressing the specific injecting-related risk behaviours they
face and addressing other health and social welfare needs. We only
identified three studies that examined effectiveness of interrupted
use of OST, but effectiveness was reduced. Similarly, available ev-
idence to examine differences in effect by dosage was limited.
Implications for research
There is low-quality evidence demonstrating the effectiveness of
OST for reducing risk behaviour and transmission of HCV and
HIV. However, there is a need to understand the role of duration
of OST use in reducing the risk of both HIV and HCV. For NSPs,
evidence needs to be strengthened. There is a need for more con-
sistent measurement in the coverage of NSPs across epidemiolog-
ical studies to obtain better effect estimates for NSPs as well as
understanding how injection of stimulants or prescription opioids
changes their effectiveness. There is a need for better studies on
NSP impact in North America and for combining studies onOST
and NSP implementation and roll-out and effect on HCV trans-
mission in general in low- and middle-income countries. Given
the body of observational evidence on effect of OST and NSP on
reducing HIV, HCV incidence and other injecting related harms,
it is not ethical to individually randomise exposure to OST or
NSP, so future trial evidence can only be derived from cluster-
randomised controlled trials or stepped wedge design. Current
guidance means that the quality of the evidence will typically be
assessed as low.
Research direction also needs to turn to implementation and un-
derstanding how NSPs and OST can be scaled up and delivered
more effectively to better respond to the health needs of PWID,
which requires observational study designs. We know that effec-
tiveness of NSP varies by geographical location, but without the
provision of counselling (psychosocial and voluntary counselling
and testing for HIV and HCV), education and drug treatment
services like opioid substitution therapy, NSPs are insufficient to
reduce epidemics of HIV and HCV in PWID (Strathdee 1997;
Vickerman 2012). More detailed assessments should examine ser-
vice delivery and their cost-effectiveness in order to ensure exist-
ing services are maintained and to promote the introduction and
scale-up of services in countries and settings with emerging or
growing epidemics of injecting and opioid drug use. This line of
research can shed light on the pathways between contextual fac-
tors and mechanisms of service delivery, and the extent to which
these influence effectiveness across different outcomes. For exam-
ple, HIV and HCV epidemics continue unchecked in Eastern Eu-
rope despite implemention of OST and NSP in some countries
(Vickerman 2014). Epidemics are growing in countries in sub-
Saharan Africa, including Tanzania and Kenya, where OST is cur-
rently being implemented, but there has been little formal evalua-
tion of different models of delivery; specific economic, social and
political contexts; and the impact of specific epidemiology of HIV
and HCV. Further, we identified only one study conducted in
a middle-income country (China) and no studies in low-income
countries. There was insufficient evidence to examine differences
in effectiveness by NSP modality or setting of OST. This reflects
a lack of evaluation of provision of OST or NSP in other settings.
Further research is needed to examine how the effect of NSP dif-
fers by service modality, including pharmacies, mobile clinics or
outreach services. Similarly, research into the effectiveness of OST
delivered in specialist services, community settings and prisons is
needed.
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While evidence for the combined effect of OST and high NSP
coverage is stronger, we only identified four studies, and only three
of those adjusted for confounders. Further evidence is needed to
understand how effectiveness may differ by modality, duration
of OST as well as impact on other health outcomes associated
with injecting drug use, including bacterial infections and mental
health, among others. Given the low quality of evidence, there is a
need to improve transparency and consistency in reporting of ob-
servational studies to facilitate systematic reviews of observational
studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aitken 2015 [pers comm]
Methods Prospective cohort study; recruitment was done via RDS, street outreach and snowball sampling
Participants Country: Australia
449 PWID, defined as ’regularly’ injecting illicit drugs in the last 6 months. Median age was 29.4 years, and 50% of
participants reported injecting daily, but there was no information on the main drug being injected
Interventions The intervention in this study was use of opioid substitution therapy (OST); OST was defined as use of OST in the
previous month. The comparison group was no current OST use
Follow-up: 196 person years
Study duration: 5 years
Outcomes HCV seroconversion as measured by HCV antibody in serum
Notes Funding source is the Australian National Health and Medical Research Council
Bruneau 2015 [pers comm]
Methods Prospective cohort study; recruitment was done via street outreach, and snowball sampling
Participants Country: Canada
285 PWID
Interventions The interventions included in this study were needle syringe exchange programme (NSP) use in the previous 3 or 6
months, use of methadone maintenance in the previous 6 months. Further detail on the intensity of engagement with
the intervention was gathered; researchers examined NSP use where 100% of needles/syringes used were obtained
by NSP and a methadone dose of 0-60 mg or 60+ mg, respectively. Comparisons were no NSP use in the previous
3 or 6 months or low NSP coverage (< 100%), no OST use in the previous 6 months, or < 59 mg of methadone
Follow-up: 589.3 person years
Study duration: 7 years
Outcomes HCV seroconversion
Notes The funding source was the Canadian Institutes of Health Research, US National Institute on Drug Abuse and the
Réseau SIDA et Maladies Infectieuses du Fonds de la Recherche en Sante du Quebec
Craine 2009
Methods Prospective cohort study
Participants Country: Wales, UK
700 PWID, defined as injecting drugs in the previous 4 weeks. 29% were female and the mean age was 27.2 years.
The main drug injected was not reported, but 42% had injected stimulants
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Craine 2009 (Continued)
Interventions The intervention was either in opioid substitution treatment or not
Follow-up: 287.3 person years
Study duration: 2 years
Outcomes HCV seroconversion
Notes Funded by the Welsh Assembly Government
Crofts 1997
Methods Retrospective cohort study
Participants Country: Australia
1741 PWID; the mean age was 29.2 years and 42% were female; main drug was not reported
Interventions The intervention was defined as either continuous or interruptedmethadone maintenance treatment; the comparison
was no methadone maintenance
Follow-up: 85.4 person years
Study duration: 4 years
Outcomes HCV seroconversion
Notes Individual funding was received from Research Fund of the Macfarlane Burnet Centre, Victorian Department of
Health and Community Services Public Health Training Programme, the Commonwealth Department of Health
and Family Service
Hagan 1995
Methods Case-control study
Participants Country: USA
46 PWID, where PWID status was defined as having injected drugs in the previous 6 months (cases). 24% of the
sample were < 25 years, 45% were female; the main drug injected was not reported
Interventions The intervention under study was ever having used a needle syringe exchange programme and comparison was never
having used a NSP
Follow-up: n/a
Study duration: 2 years
Outcomes HCV seroconversion defined by presence of HCV antibodies
Notes Funded by the American Foundation for AIDS Research
36Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Hagan 1999
Methods Prospective cohort study
Participants Country: USA
2462 PWID, defined as having injected drugs in the previous 12 months. 19% were < 25 years, 38% were female,
54% injected heroin and 59% injected daily
Interventions The intervention under study was either current sporadic or current regular needle syringe exchange programme use;
the comparison was no use of the NSP
Follow-up: 209 person years
Study duration: 2 years
Outcomes HCV seroconversion defined by presence of HCV antibodies (the timeframe for seroconversion was within the
previous 12 months)
Notes Funded by the National Institute on Drug Abuse and Centre for Disease Control
Holtzman 2009
Methods Prospective cohort study; recruitment was done via RDS and street outreach
Participants Country: USA
4663 PWID, defined as injecting drugs in the previous 6 or 12 months. 28% were less than 21 years old, 38% were
female; main drug injected was not reported, but 49% injected daily
Interventions The intervention was participation (yes/no) in a needle syringe exchange programme (NSP) in either the previous 3
months or 6 months
Follow-up: n/a
Study duration: 10 years
Outcomes HCV seroconversion measured by the presence of HCV antibodies
Notes Funding source not specified
Hope 2011
Methods Cross-sectional study. Recruitment of study participants was done via RDS
Participants Country: England, UK
299 PWID, defined as having injected drugs in the previous 4 weeks. 17% were < 25 years old, 23% were female,
94% injected opiates, 40% injected daily
Interventions The interventions were as follows:
1. Low NSP coverage and not on OST
2. Low NSP coverage and OST
3. High NSP coverage and no OST
4. High NSP coverage and OST
Comparisons were no current use of OST, no or low NSP coverage
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Hope 2011 (Continued)
Follow-up: n/a
Study duration: 6 months
Outcomes HCV seroconversion defined as HCV RNA positive and HCV antibody negative (dried blood spot testing); the
window period for the outcome was 51-75 days (range)
Notes Funded by the National Treatment Agency for Substance Use and Health Protection Agency
Hope 2015 [pers comm]
Methods Cross-sectional study; recruitment of study participants was done via RDS
Participants Country: England, UK
948PWID, defined as having injected drugs in the previous 4 weeks. Median age was 33 years, 48% injected heroin
as their main drug, but 64% had injected crack/cocaine in the previous month, 19% were female and 53% injected
daily
Interventions The interventions were as follows:
1. Low NSP coverage and not on opioid substitution treatment OST
2. Low NSP coverage and OST
3. High NSP coverage and no OST
4. High NSP coverage and OST
Comparisons were no current use of OST, no or low NSP coverage
Follow-up: 6 months
Outcomes HCV seroconversion defined as HCV RNA positive and HCV antibody negative (dried blood spot testing); the
window period for the outcome was 51-75 days (range)
Follow-up: n/a
Study duration: 6 months
Notes Funded by National Treatment Agency for Substance Use and the Health Protection Agency
Judd 2015 [pers comm]
Methods Prospective cohort study; recruitment was conducted via privileged access interviews and snowball sampling
Participants Country: England, UK
272 PWID, defined as having injected drugs in the previous 4 weeks. Median age was 27.6 years, 29% were female,
35% mainly injecting heroin, 84% injected daily
Interventions The intervention of interest was use of methadone maintenance treatment in the previous 6 months or longer,
compared to no methadone in the same time period
Follow-up:116.7 person years
Study duration: 2 years
Outcomes HCV seroconversion
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Judd 2015 [pers comm] (Continued)
Notes Funded by the UK Department of Health
Lucidarme 2004
Methods Prospective cohort study; recuitment was conducted at drug treatment centres
Participants Country: France
321 PWID, defined as ever having injected drugs. Median age was 26.9 years, 17.6% were female, 28% injected
opiates, 84% injected daily
Interventions The intervention under study was having received OST in the 3 months prior to study enrollment; the comparison
was no OST in the 3 months prior to study enrollment
Follow-up: 178.4 person years
Study duration: 1 year
Outcomes Seroconversion measured as the presence of HCV antibodies in oral fluid and serum on positive tests; the window
period for the outcome was the midpoint between previous negative oral fluid test and first positive serum test
Notes Funded by the Agence Nationale de Recherche su le SIDA, Institute de Veille Sanitaire, Programme Hospitalier
de Recherce Clinique, Direction Departementale de l’Action Sanitaire et Sociale du Nord, Academie Nationale de
Medecine
Maher 2015
Methods Prospective cohort study; recruitment was conducted in community settings and in low-threshold drug treatment
settings
Participants Country: Australia
294 PWID, defined as injection in the previous 6 months. Median age was 24 years, 32% were female, 69% injected
heroin
Interventions The intervention under study was having received OST in the previous 6 months; the comparison was no OST in
the previous 6 months
Follow-up: 212.86 person years
Study duration: 3 years
Outcomes Seroconversion as measured by anti-HCV serology at baseline using 1-2 third-generation enzyme-linked immunosor-
bent assays. PCR testing to detect HCV RNA on all final HCV antibody negative specimens
Notes Funded by the Australian National Health and Medical Research Council
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Mehta 2015 [pers comm]
Methods Prospective cohort study; recruitment was conducted through community-based outreach
Participants Country: USA
471 PWID, defined as having injected within the preceding 11 years. Median age was 34 years, 18.3% were female,
65% injected heroin and cocaine, 92% had injected in the previous year at baseline
Interventions The intervention under study was being in methadone treatment in the previous 6 months; the comparison was no
methadone treatment in the previous 6 months
Follow-up: 166.5 person years
Study duration: 20 years
Outcomes HCV seroconversion, measured through serum samples
Notes Funded by the National Institute on Drug Abuse
Nolan 2014
Methods Prospective cohort study; recruitment included snowball sampling
Participants Country: Canada
3741 PWID, defined as having injected drugs in the previous 4 weeks. 30% were female, 34% injected opiates and
the mean age was 34 years among methadone users and 23 years among non-methadone users
Interventions The interventions under study were:
1. Active participation in methadone maintenance treatment (MMT) in last 6 months
2. MMT once during follow-up,
3. MMT > 2 times during follow-up
Comparison was no use of MMT within the same time periods
Follow-up: 2108.4 person years
Study duration: 16 years
Outcomes HCV seroconversion defined by presence of HCV antibodies
Notes Funded by the US National Institutes on Drug Abuse
Page 2015 [pers comm]
Methods Prospective cohort study; recruitment occurred through street outreach
Participants Country: USA
552 PWID, defined as people who have injected drugs in the previous month and less than 30 years old. 42.5% were
< 22 years, 22% were female and 61% injected heroin/heroin mixed in the previous month
Interventions The intervention under study was use of a NSP in the previous 3 months and the comparison was no use of NSP
Follow-up: 681.3 person years
Study duration: 15 years
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Page 2015 [pers comm] (Continued)
Outcomes HCV seroconversion defined by presence of HCV antibodies or HCV RNA
Notes Funded by the National Institute on Drug Abuse
Palmateer 2014a
Methods Cross-sectional study; participants were recruited at NSPs
Participants Country: Scotland, UK
7954 PWID, defined as ever having injected drugs (but 80% had injected in previous 6 months). Mean age is 34
years, 27.5% are female, 55.3% inject daily and 17% injected stimulants
Interventions The interventions were defined as:
1. Needle syringe exchange (NSP) coverage: low vs high
2. Paraphernalia coverage: low vs high
3. Opioid substitution treatment (OST): current vs not current
4. NSP and OST combined: low NSP, no OST vs low NSP with OST, high NSP no OST, high NSP OST, did
not inject OST
5. NSP, paraphernalia, and OST combined: low NSP, low para, no OST vs low NSP, low para with OST, high
NSP, low para, no OST, high NSP, low para, OST, high NSP, high para, no OST, high NSP, high para, OST, did
not inject OST
The comparisons were no OST or no/low NSP use
Follow-up: 602.7 person years
Study duration: 4 years
Outcomes The outcome was HCV seroconversion defined as being HCV antibody negative and HCV RNA positive
Notes Funded by the Scottish Government
Patrick 2001
Methods Prospective cohort study; recruitment included snowball sampling
Participants Country: Canada
1345 PWID, defined as having injected drugs in the previous 4 weeks. 30% were female, the median age was 34
years, 63% injected opiates and 54% injected stimulants, 54% injected daily
Interventions The intervention under study was
1. Attendance at least once per week at NSP in previous 6 months (yes or no)
2. Methadone maintenance treatment in previous 6 months (yes or no)
The comparison was NSP attendance or no methadone in the previous 6 months
Follow-up: 207.9 person years
Study duration: 3 years
Outcomes HCV seroconversion measured by HCV antibody positivity
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Patrick 2001 (Continued)
Notes Funding source was not specified
Rezza 1996
Methods Case-control study; recruitment methods employed a convenience sample of service attenders
Participants Country: Italy
746 PWID, defined as being a heroin user. 21% were < 28 years, 3% were female, 100% injected opiates and 32%
also injected stimulants, 69% injected daily
Interventions The intervention under study was being in methadone maintenance treatment in the previous 6 months, the com-
parison was no methadone maintenance in the same time period
Follow-up: 73.4 person years
Study duration: 2 years
Outcomes HCV seroconversion, measured by HCV antibody positivity in serum samples
Notes Funded by the Progretto AIDS, Ministero della Sanita-Instituto Superiore di Sanita
Roy 2007
Methods Serial cross-sectional survey; recruitment methods employed service attenders at drug treatment programmes
Participants Country: Canada
1380 PWID, defined as having injected in the previous 6 months. Mean age was 31.8 years, 27% were female, 19%
injected opiates and 75% injected stimulants
Interventions The intervention under study was using an NSP in the previous 6 months, and the comparison was no use of the
NSP
Follow-up: 267 person years
Study duration: 6 years
Outcomes HCV RNA positive on anti-HCV negative (oral fluid). HCV seroconversions were attributed to the midpoint
between the previous negative and first positive test results
Notes Funded by the Health Canada, Ministere de la Sante et des Services Sociaux du Quebec
Ruan 2007
Methods Prospective cohort study; recruitment occurred via community outreach and snowball sampling
Participants Country: China
379 PWID, defined as having injected drugs in the previous 3 months. 44% were < 28 years and 100% injected
opiates. There was no information on sex or frequency of injecting
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Ruan 2007 (Continued)
Interventions The intervention of interest was lifetime experience of methadone maintenance treatment (yes or no)
Follow-up: 258 person years
Study duration: 3 years
Outcomes HCV antibody positivity in serum samples (incidence density); the time of seroconversion was the midpoint between
the previous negative and first positive HCV antibody test result
Notes Funded by the Ministry of Science and Technology of China, the National Natural Science Foundation of China,
China Comprehensive Integrated Programmes for Research on AIDS, theNational Institute of Allergy and Infectious
Diseases and the National Institutes of Health
Spittal 2012
Methods Prospective cohort study; recruitment via community outreach and snowball sampling
Participants Country: Canada
377 PWID, defined as having injected in the previous 4 weeks. Median age was 23 years, 53% were female, 18%
injected opiates, 10% injected stimulants, 18% injected daily
Interventions The intervention of interest was being in methadone maintenance treatment (yes or no) at the time of survey;
comparison was no current use of methadone maintenance
Follow-up:338.6 person years
Study duration: 6 years
Outcomes HCV antibody positivity in serum samples (incidence density); the time of seroconversion was the midpoint between
the previous negative and first positive HCV antibody test result
Notes Funded by the Institute for Aboriginal Peoples Health and the Canadian Institutes for Health Research
Thiede 2000
Methods Prospective cohort study; recruitment from a drug treatment setting
Participants Country: USA
716 PWID, defined as having injected drugs in the previous 4 weeks. 5.4% were < 25 years, 49% were female, 23%
injected stimulants and 25% injected daily
Interventions The interventions under study were:
1. Left methadone maintenance treatment (MMT) at least once during follow-up but were re-enrolled at their
follow-up visit
2. Remained in MMT throughout the follow-up period
The comparison was no MMT.
Follow-up: 80 person years
Study duration: 4 years
Outcomes HCV seroconversion, as demonstrated by the presence of HCV antibodies in serum
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Thiede 2000 (Continued)
Notes Funded by the Centers for Disease Control and Prevention
Thorpe 2002
Methods Prospective cohort study; recruitment via street outreach, targeted advertising, and peer referrals
Participants Country: USA
702 PWID, defined as having injected in the previous 6 months. 53% were aged 18-22 years, 49% were female,
23% injected stimulants and 39% injected daily
Interventions The intervention of interest was use of an NSP in the previous 6 months and the comparison was no use of the NSP
Follow-up: 327.2 person years
Study duration: 2 years
Outcomes HCV seroconversion as demonstrated by the presence of HCV antibodies in serum; time of seroconversion was taken
to be the midpoint between the previous negative and first positive HCV antibody test result
Notes Funding source was not specified
Tsui 2014
Methods Prospective cohort study; recruitment via street outreach
Participants Country: USA
992 PWID, defined as having injected in the previous 4 weeks and aged < 30 years. 16% were aged 15-18 years,
32% were female, 60% injected opiates and 33.2% injected stimulants
Interventions The interventions of interest included:
1. Opiate agonist detoxification in previous 3 months
2. Opiate agonist therapy maintenance treatment in previous 3 months. Recent opioid agonist therapy included
treatment with buprenorphine or methadone anytime within the past year at the baseline screening interview,
within the past 3 months at quarterly interviews for participants in waves 1 and 3, and within the past week for
participants in wave 2
The comparison was no opiate agonist therapy in the same time frame
Follow-up: 680 person years
Study duration: 13 years
Outcomes HCV seroconversion. Incidence was calculated using behavior or characteristic at the previous period that participant
was seronegative forHCV (uninfected during follow-up) or the firstHCV-seropositive risk period (incident infections)
. Incident acute HCV infections were: a new test result positive for HCV RNA and/or anti-HCV after a previously
documented test result negative for anti-HCV; or a positive HCV RNA test result concomitant with a negative anti-
HCV test result
Notes Funded by the National Institute on Drug Abuse, National Institute of Health, National Institute on Alcohol and
Alcoholism
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Vallejo 2015
Methods Prospective cohort study; recruitment was street-based and employed targeted sampling and chain-referral methods
Participants Country: Spain
513 PWID; PWID were required to have used heroin at least 12 days and at least 1 day in the past 3 months. 40%
were < 25 years, 27% were female, 31% injected stimulants. There was no information on daily injecting
Interventions The intervention of interest was methadonemaintenance; further details of the intervention (e.g. intensity or duration
of engagement in the intervention) was not specified, the comparison was no use of methadone maintenance
Follow-up: 105.4 peron years
Study duration: 3 years
Outcomes HCV seroconversion, defined by HCV antibody positivity by dried blood spot testing
Notes Funded by the Foundation for AIDS Prevention and Research
Van Beek 1998
Methods Retrospective cohort study; recruitment at drug treatment services
Participants Country: Australia
1078 PWID, 61.5% were < 20 years, 55.9% were female, 19% injected opiates, 27.9% injected stimulants
Interventions The intervention under study was ever having received methadone; the comparison was no methadone
Follow-up:148.2 person years
Study duration: 2 years
Outcomes HCV seroconversion
Notes Funded by the Australian National Council on AIDS and Related Diseases
Van Den Berg 2007
Methods Prospective cohort study; enrollment occurred through ’open’ recruitment
Participants Country: Netherlands
168 PWID, defined as those who had ever injected drugs. Median age was 31.4 years, 33%were female, 33% injected
opiates and 51% injected stimulants, 51.7% injected daily
Interventions The interventions of interest were measured as follows:
1. Incomplete harm reduction: any dose of methadone daily, injection in previous 6 months, irregular or no use
of NSP; OR 0-59 mg of methadone daily in past 6 months, always use NSP
2. Full harm reduction: ≥ 60 mg of methadone daily in past 6 months; no injecting drug use; ≥ 60 mg
methadone daily, injecting drug use in past 6 months, always use NSP
3. Limited dependence on harm reduction: 1-59 mg of methadone in past 6 months, no injecting drug use
4. No dependence on harm reduction: no methadone in in past 6 months, no injection in past 6 months.
The comparsion was no methadone in the past 6 months, and/or no use of NSP or no injection
Follow-up: 598.56 person years
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Van Den Berg 2007 (Continued)
Study duration: 22 years
Outcomes HCV seroconversion
Notes Funded by the Netherlands National Institute for Public Health and the Environment
White 2014
Methods Prospective cohort study; recruitment via snowball sampling, social networks, RDS, and targeted outreach sampling
Participants Country: Australia
166 PWID, defined as those who had injected drugs in the previous 12 months. Median age was 27 years, 25% were
female. Participants mainly injecting opioids, but frequency of injecting was not reported
Interventions The intervention assessed was having accessed a needle syringe exchange programme or opioid substitution treatment
in the previous 6 months, the comparison was no use of the NSP or OST in the same time frame
Follow-up: 215.2 person years.
Study duration: 3 years
Outcomes HCV seroconversion defined as being negative for HCV antibodies and positive for HCV RNA
Notes Funded by the National Health and Medical Research Council
HCV: hepatitis C virus; NSP: needle syringe programme;OST: opioid substitution therapy; PCR: polymerase chain reaction; PWID:
people who inject drugs; RDS: respondent-driven sampling.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aubisson 2006 No outcome of interest
Azim 2005 No outcome of interest
Bayoumi 2008 No intervention of interest: no OST or NSP
Burt 2007 No outcome of interest
Buxton 2010 No outcome of interest; no comparison of interest: all participants on OST
Collins 2009 No outcome of interest
Cox 2000 No outcome of interest
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(Continued)
Crofts 1993 No intervention of interest: no OST or NSP
De Vos 2012 No outcome of interest; simulation study
Des Jarlais 2005 No outcome of interest
Des Jarlais 2007 No outcome of interest
Dubois-Arber 2008 No outcome of interest
Emmanuelli 2005 No outcome of interest
Esteban 2003 No outcome of interest. No comparison of interest: all participants on OST
Falster 2009 No outcome of interest
Fatseas 2012 No outcome of interest
Fhima 2001 No comparison of interest: all participants on OST
Fudala 2003 No outcome of interest
Fuller 2004 No intervention of interest: no OST or NSP
Galeazzl 1995 No outcome of interest; no intervention of interest: no OST or NSP
Gambashidze 2008 No outcome of interest
Garfein 1998 No outcome of interest; no intervention of interest: no OST or NSP
Garfein 2007 No outcome of interest; no intervention of interest: no OST or NSP
Garten 2004 No intervention of interest: no OST or NSP
Gervasoni 2012 No outcome of interest
Goldberg 1998 No outcome of interest
Goldberg 2001 No outcome of interest
Goswami 2014 No outcome of interest
Grebely 2013 Editorial
Grebely 2014 No intervention of interest: no OST or NSP
Guadagnino 1995 No outcome of interest; No intervention of interest: no OST or NSP
Hagan 2000 No outcome of interest; no intervention of interest: no OST or NSP
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(Continued)
Heimer 1999 No outcome of interest
Higgs 2012 No outcome of interest
Jackson 2014 No comparison of interest: all participants on OST
Javanbakht 2014 No outcome of interest; simulation study
Judd 2005 No intervention of interest: no OST or NSP
Kwon 2009 No outcome of interest; simulation study
Lai 2001 No intervention of interest: no OST or NSP
Larney 2015 No comparison of interest
Mansson 2000 No outcome of interest
Mikolajczyk 2013 No intervention of interest: no OST or NSP
Moshkovich 2000 No outcome of interest
Muga 2006 No outcome of interest
Nasir 2011 No outcome of interest
Page 2009 No intervention of interest: no OST or NSP
Page 2013 No intervention of interest: no OST or NSP
Palmateer 2014b No intervention of interest: no OST or NSP
Paquette 2010 No intervention of interest: no OST or NSP
Parrino 2003 Overview
Pedrana 2009 No intervention of interest: no OST or NSP
Peles 2011 No comparison of interest: all on OST
Pollack 2001 No outcome of interest; simulation model
Pratt 2002 No outcome of interest
Robotin 2004 No intervention of interest: no OST or NSP
Rohrig 1990 No outcome of interest
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Roux 2012 No outcome of interest. No comparison of interest: all participants on OST
Roux 2014 No outcome of interest
Roy 2009 No intervention of interest: no OST or NSP
Roy 2012 No intervention of interest: no OST or NSP
Ruan 2013 No intervention of interest: no OST or NSP
Samo 2013 No outcome of interest
Sanders-Buell 2013 No outcome of interest
Seal 2004 No outcome of interest
Selvey 1997 No comparison of interest: all participants on OST
Sendi 2003 No intervention of interest: no OST or NSP
Shannon 2010 No intervention of interest: no OST or NSP
Shi 2007 No comparison of interest: all participants on OST
Solomon 2010 No intervention of interest: no OST or NSP
Spencer 1997 No intervention of interest: no OST or NSP
Steffen 2001 No intervention of interest: no OST or NSP
Stein 2009 No intervention of interest: no OST or NSP
Stephens 2011 No outcome of interest. No intervention of interest: no OST or NSP
Stephens 2013 No intervention of interest: no OST or NSP
Strathdee 1997 No outcome of interest
Sullivan 2005 No outcome of interest. No comparison of interest: all participants on OST
Sylvestre 2006 No outcome of interest
Tait 2013a No outcome of interest. No intervention of interest: no OST or NSP
Tait 2013b No outcome of interest. No intervention of interest: no OST or NSP
Todd 2015 No intervention of interest (NSP shuts down for some of the follow-up)
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Tracy 2014 No intervention of interest: no OST or NSP
Tsirogianni 2013 No intervention of interest: no OST or NSP
Tsui 2009 No intervention of interest: no OST or NSP
Valdez 2011 No outcome of interest. No intervention of interest: no OST or NSP
Van Ameijden 1993 No intervention of interest: no OST or NSP
Van den Hoek 1990 No outcome of interest
Van den Laar 2009 No outcome of interest. No intervention of interest: no OST or NSP
Van den Laar 2010 No outcome of interest. No intervention of interest: no OST or NSP
Van Santen 2013 No outcome of interest
Villano 1997 No intervention of interest: no OST or NSP
Wand 2009 No intervention of interest: doesn’t specify OST, only that it is drug treatment
Wang 2014 No comparison of interest: all participants on OST
Widell 2009 No intervention of interest: no OST or NSP
Winkelstein 2013 No outcome of interest
Woody 2008 No outcome of interest
Yang 2011 No outcome of interest
Yen 2012 No outcome of interest
Zhao 2005 No outcome of interest
Zhou 2015 No comparison of interest: all participants on OST
Zou 2015 No comparison of interest: all participants on OST
Zunt 2006 No outcome of interest
NSP: needle syringe programme; OST: opioid substitution therapy.
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Characteristics of studies awaiting assessment [ordered by study ID]
Bruneau 2016
Methods Prospective cohort
Participants 313 HCV-seronegative PWID (injection in the previous month) were enrolled with at least one follow-up visit. 22%
were female, 43% were under 30 years old and 58% injected cocaine
Interventions Opioid agonist therapy (1-59 mg, methadone or suboxone, ≥ 60 mg methadone) and injection material coverage
(100% safe sources vs no)
Outcomes Seroconversion to HCV antibody positive
Notes The study was conducted in Montreal, Canada. No funding source is specified
Chun 2006
Methods -
Participants -
Interventions -
Outcomes -
Notes There is no abstract, and the text is in Chinese.
Duan 2013
Methods -
Participants -
Interventions -
Outcomes -
Notes There is no abstract, and the text is in Chinese.
He 2003
Methods -
Participants -
Interventions -
Outcomes -
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He 2003 (Continued)
Notes There is no abstract, and the text is in Chinese.
He 2004
Methods -
Participants -
Interventions -
Outcomes -
Notes There is no abstract, and the text is in Chinese.
Mathei 2016
Methods -
Participants -
Interventions -
Outcomes -
Notes The text is in French, and there is little information in the abstract
O’Keefe 2016
Methods Prospective cohort recruited between 2011 and 2015
Participants People who inject drugs, defined as regular injectors (at least one a month in the 6 months prior to recruitment), a
total of 502 participants, approximately 36% were female and mean age 30 was years
Interventions Current opoid substitution therapy prescription; NSP as usual source of syringe acquisition in the past month,
measure of injections covered by sterile syringe (syringes acquired divided by syringes distributed divided by past
week injecting frequency)
Outcomes HCV RNA positive among negative samples
Notes Data drawn from the Melbourne injecting drug use cohort study (MIX). Funding provided by the Colonial Foun-
dation Trust and the National Reserch Council
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Ray Saraswati 2015
Methods Longitudinal incidence study, participants recruited in community settings through peer referrals in places where
drugs are used
Participants People who inject drugs defined as injection at least once in the previous 3 months and residing in Delhi. A total of
2292 PWID recruited of whom all were male; median age was 29 years
Interventions Accessed NSP in the previous 3 months
Outcomes anti HCV negative and HCV RNA positive
Notes Funding received from the Canadian Government (Department of Foreign Affairs, Trade and Development Canada)
. No incidence data reported, but need to contact authors for measures
Siedentopf 2002
Methods -
Participants -
Interventions -
Outcomes -
Notes There is no abstract, and the text is in German.
Wada 2004
Methods -
Participants -
Interventions -
Outcomes -
Notes There is no abstract, and the text is in Japanese.
HCV: hepatitis C virus; NSP: needle syringe programme; PWID: people who inject drugs.
53Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
D A T A A N D A N A L Y S E S
Comparison 1. Current OST versus no OST
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence adjusted
analyses by region
12 6361 Risk Ratio (Random, 95% CI) 0.50 [0.40, 0.63]
1.1 North America 5 2245 Risk Ratio (Random, 95% CI) 0.57 [0.42, 0.76]
1.2 Europe 5 3494 Risk Ratio (Random, 95% CI) 0.43 [0.27, 0.68]
1.3 Australia 2 622 Risk Ratio (Random, 95% CI) 0.42 [0.25, 0.72]
2 HCV incidence adjusted analysis
by study design
12 6361 Risk Ratio (Random, 95% CI) 0.50 [0.40, 0.63]
2.1 Prospective cohort 10 3467 Risk Ratio (Random, 95% CI) 0.51 [0.40, 0.65]
2.2 Cross-sectional surveys 2 2894 Risk Ratio (Random, 95% CI) 0.46 [0.23, 0.89]
3 HCV incidence unadjusted
analyses by different modes of
OST provision
9 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Ever used OST 3 375 Risk Ratio (Random, 95% CI) 0.81 [0.52, 1.27]
3.2 Interrupted OST use 3 1157 Risk Ratio (Random, 95% CI) 0.80 [0.57, 1.10]
3.3 Detoxification 1 552 Risk Ratio (Random, 95% CI) 1.45 [0.79, 2.66]
3.4 High dose 2 453 Risk Ratio (Random, 95% CI) 0.52 [0.29, 0.94]
3.5 Low dose 2 453 Risk Ratio (Random, 95% CI) 0.85 [0.44, 1.65]
Comparison 2. Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 8 5235 Risk Ratio (Random, 95% CI) 0.42 [0.31, 0.58]
Comparison 3. Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 9 5782 Risk Ratio (Random, 95% CI) 0.51 [0.40, 0.64]
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Comparison 4. Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross-sectional studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 10 3467 Risk Ratio (Random, 95% CI) 0.51 [0.40, 0.65]
Comparison 5. OST versus no OST, unadjusted analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 16 9499 Risk Ratio (Random, 95% CI) 0.57 [0.45, 0.73]
Comparison 6. High NSP coverage versus no/low NSP coverage
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence adjusted
analyses by region
5 3530 Risk Ratio (Random, 95% CI) 0.79 [0.39, 1.61]
1.1 North America 3 627 Risk Ratio (Random, 95% CI) 1.25 [0.63, 2.46]
1.2 Europe 2 2903 Risk Ratio (Random, 95% CI) 0.24 [0.09, 0.62]
2 HCV incidence adjusted
analyses by study design
5 3530 Risk Ratio (Random, 95% CI) 0.95 [0.50, 1.82]
2.1 Prospective cohorts 3 627 Risk Ratio (Random, 95% CI) 1.44 [1.01, 2.05]
2.2 Cross-sectional surveys 2 2903 Risk Ratio (Random, 95% CI) 0.24 [0.09, 0.62]
Comparison 7. Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 4 3245 Risk Ratio (Random, 95% CI) 0.77 [0.28, 2.13]
55Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 8. Sensitivity analysis: high NSP versus low/no NSP, excluding cross-sectional surveys
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 3 627 Risk Ratio (Random, 95% CI) 1.25 [0.63, 2.46]
Comparison 9. High NSP coverage versus low/no coverage, unadjusted estimates
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 7 6455 Risk Ratio (Random, 95% CI) 0.78 [0.39, 1.55]
Comparison 10. Low NSP coverage versus no coverage
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence, adjusted
analyses
6 2765 Risk Ratio (Random, 95% CI) 1.43 [0.82, 2.49]
Comparison 11. Low NSP coverage versus no NSP, unadjusted analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HCV incidence 9 3242 Risk Ratio (Random, 95% CI) 1.41 [0.95, 2.09]
Comparison 12. Combined OST and high/low NSP versus no OST and low/no NSP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1HCV incidence adjusted analyses 3 6197 Risk Ratio (Random, 95% CI) 0.45 [0.22, 0.94]
1.1 High NSP coverage 3 3241 Risk Ratio (Random, 95% CI) 0.26 [0.07, 0.89]
1.2 Low NSP coverage 2 2956 Risk Ratio (Random, 95% CI) 0.87 [0.44, 1.68]
2 HCV incidence unadjusted
analyses
4 6427 Risk Ratio (Random, 95% CI) 0.47 [0.27, 0.80]
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2.1 Combined OST and high
NSP versus no OST and low/
no NSP
4 3356 Risk Ratio (Random, 95% CI) 0.29 [0.13, 0.65]
2.2 Combined OST and low
NSP versus no OST and low/
no NSP
3 3071 Risk Ratio (Random, 95% CI) 0.76 [0.44, 1.33]
Analysis 1.1. Comparison 1 Current OST versus no OST, Outcome 1 HCV incidence adjusted analyses by
region.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 1 Current OST versus no OST
Outcome: 1 HCV incidence adjusted analyses by region
Study or subgroup anti HCV negative HCV new cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 North America
Bruneau 2015 [pers comm] 183 102 -0.30111 (0.23047) 25.0 % 0.74 [ 0.47, 1.16 ]
Mehta 2015 [pers comm] 297 27 -0.19845 (0.743466) 2.4 % 0.82 [ 0.19, 3.52 ]
Nolan 2014 820 184 -0.75502 (0.245775) 22.0 % 0.47 [ 0.29, 0.76 ]
Thiede 2000 76 4 -0.91629 (1.540881) 0.6 % 0.40 [ 0.02, 8.20 ]
Tsui 2014 407 145 -0.94161 (0.401923) 8.2 % 0.39 [ 0.18, 0.86 ]
Subtotal (95% CI) 1783 462 58.3 % 0.57 [ 0.42, 0.76 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.08, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00019)
2 Europe
Craine 2009 269 17 -1.07881 (0.53832) 4.6 % 0.34 [ 0.12, 0.98 ]
Judd 2015 [pers comm] 100 49 -0.71335 (0.550311) 4.4 % 0.49 [ 0.17, 1.44 ]
Lucidarme 2004 149 16 -0.8916 (0.626718) 3.4 % 0.41 [ 0.12, 1.40 ]
Palmateer 2014a 2396 392 -0.65393 (0.41714) 7.6 % 0.52 [ 0.23, 1.18 ]
Rezza 1996 85 21 -1.06471 (0.606502) 3.6 % 0.34 [ 0.11, 1.13 ]
Subtotal (95% CI) 2999 495 23.6 % 0.43 [ 0.27, 0.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00037)
3 Australia
Maher 2015 315 53 -0.77653 (0.309169) 13.9 % 0.46 [ 0.25, 0.84 ]
White 2014 120 7 -0.58779 (0.778217) 2.2 % 0.56 [ 0.12, 2.55 ]
White 2014 114 13 -1.72988 (0.815154) 2.0 % 0.18 [ 0.04, 0.88 ]
0.01 0.1 1 10 100
Favours OST Favours no OST
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(. . . Continued)
Study or subgroup anti HCV negative HCV new cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 549 73 18.1 % 0.42 [ 0.25, 0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 5331 1030 100.0 % 0.50 [ 0.40, 0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.50, df = 12 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 5.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.50, df = 2 (P = 0.47), I2 =0.0%
0.01 0.1 1 10 100
Favours OST Favours no OST
Analysis 1.2. Comparison 1 Current OST versus no OST, Outcome 2 HCV incidence adjusted analysis by
study design.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 1 Current OST versus no OST
Outcome: 2 HCV incidence adjusted analysis by study design
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Prospective cohort
Bruneau 2015 [pers comm] 183 102 -0.30111 (0.23047) 25.0 % 0.74 [ 0.47, 1.16 ]
Craine 2009 269 17 -1.07881 (0.53832) 4.6 % 0.34 [ 0.12, 0.98 ]
Judd 2015 [pers comm] 100 49 -0.71335 (0.550311) 4.4 % 0.49 [ 0.17, 1.44 ]
Lucidarme 2004 149 16 -0.8916 (0.626718) 3.4 % 0.41 [ 0.12, 1.40 ]
Maher 2015 315 53 -0.77653 (0.309169) 13.9 % 0.46 [ 0.25, 0.84 ]
Mehta 2015 [pers comm] 297 27 -0.19845 (0.743466) 2.4 % 0.82 [ 0.19, 3.52 ]
Nolan 2014 820 184 -0.75502 (0.245774) 22.0 % 0.47 [ 0.29, 0.76 ]
Thiede 2000 76 4 -0.91629 (1.540881) 0.6 % 0.40 [ 0.02, 8.20 ]
Tsui 2014 407 145 -0.94161 (0.401923) 8.2 % 0.39 [ 0.18, 0.86 ]
White 2014 114 13 -1.72988 (0.815154) 2.0 % 0.18 [ 0.04, 0.88 ]
0.01 0.1 1 10 100
Favours OST Favours no OST
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Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
White 2014 120 7 -0.58779 (0.778217) 2.2 % 0.56 [ 0.12, 2.55 ]
Subtotal (95% CI) 2850 617 88.7 % 0.51 [ 0.40, 0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.09, df = 10 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
2 Cross-sectional surveys
Palmateer 2014a 2396 392 -0.65393 (0.41714) 7.6 % 0.52 [ 0.23, 1.18 ]
Rezza 1996 85 21 -1.06471 (0.606502) 3.6 % 0.34 [ 0.11, 1.13 ]
Subtotal (95% CI) 2481 413 11.3 % 0.46 [ 0.23, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 5331 1030 100.0 % 0.50 [ 0.40, 0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.50, df = 12 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 5.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Current OST versus no OST, Outcome 3 HCV incidence unadjusted analyses by
different modes of OST provision.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 1 Current OST versus no OST
Outcome: 3 HCV incidence unadjusted analyses by different modes of OST provision
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Ever used OST
Ruan 2007 39 47 -0.69314 (0.4775) 23.0 % 0.50 [ 0.20, 1.27 ]
Vallejo 2015 95 42 -0.10536 (0.29672) 59.5 % 0.90 [ 0.50, 1.61 ]
Van Beek 1998 126 26 0.07696 (0.54795) 17.5 % 1.08 [ 0.37, 3.16 ]
Subtotal (95% CI) 260 115 100.0 % 0.81 [ 0.52, 1.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.42, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Interrupted OST use
Crofts 1997 63 10 -0.41551 (0.0914) 45.8 % 0.66 [ 0.55, 0.79 ]
Nolan 2014 820 184 -0.06827 (0.00272) 53.1 % 0.93 [ 0.93, 0.94 ]
Thiede 2000 74 6 -0.22341 (1.54688) 1.1 % 0.80 [ 0.04, 16.58 ]
Subtotal (95% CI) 957 200 100.0 % 0.80 [ 0.57, 1.10 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 14.43, df = 2 (P = 0.00074); I2 =86%
Test for overall effect: Z = 1.38 (P = 0.17)
3 Detoxification
Tsui 2014 403 149 0.37156 (0.30935) 100.0 % 1.45 [ 0.79, 2.66 ]
Subtotal (95% CI) 403 149 100.0 % 1.45 [ 0.79, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
4 High dose
Bruneau 2015 [pers comm] 183 102 -0.99425 (0.3951) 44.2 % 0.37 [ 0.17, 0.80 ]
Van Den Berg 2007 122 46 -0.38566 (0.33669) 55.8 % 0.68 [ 0.35, 1.32 ]
Subtotal (95% CI) 305 148 100.0 % 0.52 [ 0.29, 0.94 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 2.17 (P = 0.030)
5 Low dose
Bruneau 2015 [pers comm] 183 102 0.13976 (0.25338) 55.7 % 1.15 [ 0.70, 1.89 ]
Van Den Berg 2007 123 45 -0.54472 (0.34278) 44.3 % 0.58 [ 0.30, 1.14 ]
Subtotal (95% CI) 306 147 100.0 % 0.85 [ 0.44, 1.65 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 2.58, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 5.72, df = 4 (P = 0.22), I2 =30%
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Analysis 2.1. Comparison 2 Sensitivity analysis: OST versus no OST, adjusted analyses excluding
unpublished datasets, Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 2 Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Craine 2009 269 17 -1.07881 (0.53832) 8.5 % 0.34 [ 0.12, 0.98 ]
Lucidarme 2004 149 16 -0.8916 (0.62671) 6.2 % 0.41 [ 0.12, 1.40 ]
Nolan 2014 820 184 -0.75502 (0.24577) 40.6 % 0.47 [ 0.29, 0.76 ]
Palmateer 2014a 2396 392 -0.65393 (0.41714) 14.1 % 0.52 [ 0.23, 1.18 ]
Rezza 1996 85 21 -1.06471 (0.6065) 6.7 % 0.34 [ 0.11, 1.13 ]
Thiede 2000 76 4 -0.91629 (1.54088) 1.0 % 0.40 [ 0.02, 8.20 ]
Tsui 2014 407 145 -0.94161 (0.40192) 15.2 % 0.39 [ 0.18, 0.86 ]
White 2014 114 7 -0.58779 (0.77821) 4.0 % 0.56 [ 0.12, 2.55 ]
White 2014 120 13 -1.72988 (0.81515) 3.7 % 0.18 [ 0.04, 0.88 ]
Total (95% CI) 4436 799 100.0 % 0.42 [ 0.31, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.01, df = 8 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 5.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at
critical risk of bias, Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 3 Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bruneau 2015 [pers comm] 183 102 -0.30111 (0.23047) 28.0 % 0.74 [ 0.47, 1.16 ]
Craine 2009 269 17 -1.07881 (0.53832) 5.1 % 0.34 [ 0.12, 0.98 ]
Lucidarme 2004 149 16 -0.8916 (0.62671) 3.8 % 0.41 [ 0.12, 1.40 ]
Maher 2015 315 53 -0.77653 (0.309169) 15.5 % 0.46 [ 0.25, 0.84 ]
Nolan 2014 820 184 -0.75502 (0.24577) 24.6 % 0.47 [ 0.29, 0.76 ]
Palmateer 2014a 2396 392 -0.65393 (0.41714) 8.5 % 0.52 [ 0.23, 1.18 ]
Thiede 2000 76 4 -0.91629 (1.54088) 0.6 % 0.40 [ 0.02, 8.20 ]
Tsui 2014 407 145 -0.94161 (0.40192) 9.2 % 0.39 [ 0.18, 0.86 ]
White 2014 120 7 -0.58779 (0.77821) 2.5 % 0.56 [ 0.12, 2.55 ]
White 2014 114 13 -1.72988 (0.81515) 2.2 % 0.18 [ 0.04, 0.88 ]
Total (95% CI) 4849 933 100.0 % 0.51 [ 0.40, 0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.68, df = 9 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross-
sectional studies, Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 4 Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross-sectional studies
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bruneau 2015 [pers comm] 183 102 -0.30111 (0.23047) 28.2 % 0.74 [ 0.47, 1.16 ]
Craine 2009 269 17 -1.07881 (0.53832) 5.2 % 0.34 [ 0.12, 0.98 ]
Judd 2015 [pers comm] 100 49 -0.71335 (0.55031) 4.9 % 0.49 [ 0.17, 1.44 ]
Lucidarme 2004 149 16 -0.8916 (0.62671) 3.8 % 0.41 [ 0.12, 1.40 ]
Maher 2015 315 53 -0.77653 (0.30916) 15.7 % 0.46 [ 0.25, 0.84 ]
Mehta 2015 [pers comm] 297 27 -0.19845 (0.74346) 2.7 % 0.82 [ 0.19, 3.52 ]
Nolan 2014 820 184 -0.75502 (0.24577) 24.8 % 0.47 [ 0.29, 0.76 ]
Thiede 2000 76 4 -0.91629 (1.54088) 0.6 % 0.40 [ 0.02, 8.20 ]
Tsui 2014 407 145 -0.94161 (0.40192) 9.3 % 0.39 [ 0.18, 0.86 ]
White 2014 114 7 -0.58779 (0.77821) 2.5 % 0.56 [ 0.12, 2.55 ]
White 2014 120 13 -1.72988 (0.81515) 2.3 % 0.18 [ 0.04, 0.88 ]
Total (95% CI) 2850 617 100.0 % 0.51 [ 0.40, 0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.09, df = 10 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 OST versus no OST, unadjusted analysis, Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 5 OST versus no OST, unadjusted analysis
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Aitken 2015 [pers comm] 81 17 -0.22314 (0.48395) 5.1 % 0.80 [ 0.31, 2.07 ]
Bruneau 2015 [pers comm] 183 102 -0.30111 (0.23047) 11.8 % 0.74 [ 0.47, 1.16 ]
Craine 2009 269 17 -1.30933 (0.5338) 4.4 % 0.27 [ 0.09, 0.77 ]
Crofts 1997 60 13 0.58778 (0.65219) 3.2 % 1.80 [ 0.50, 6.46 ]
Hope 2015 [pers comm] 916 3 -1.42712 (0.80208) 2.2 % 0.24 [ 0.05, 1.16 ]
Hope 2015 [pers comm] 917 2 0.27002 (1.4271) 0.8 % 1.31 [ 0.08, 21.48 ]
Hope 2015 [pers comm] 917 2 0.43825 (1.2301) 1.0 % 1.55 [ 0.14, 17.27 ]
Judd 2015 [pers comm] 100 49 -0.75502 (0.54024) 4.3 % 0.47 [ 0.16, 1.36 ]
Lucidarme 2004 149 16 -1.07881 (0.56051) 4.0 % 0.34 [ 0.11, 1.02 ]
Maher 2015 315 53 -0.84397 (0.29067) 9.6 % 0.43 [ 0.24, 0.76 ]
Mehta 2015 [pers comm] 297 27 -0.51083 (0.73632) 2.6 % 0.60 [ 0.14, 2.54 ]
Nolan 2014 820 184 -0.40048 (0.20113) 13.0 % 0.67 [ 0.45, 0.99 ]
Palmateer 2014a 2396 392 -0.67334 (0.2889) 9.7 % 0.51 [ 0.29, 0.90 ]
Spittal 2012 103 45 0.74668 (0.47631) 5.2 % 2.11 [ 0.83, 5.37 ]
Thiede 2000 76 4 -1.20397 (1.50155) 0.7 % 0.30 [ 0.02, 5.69 ]
Tsui 2014 407 145 -1.17118 (0.39166) 6.8 % 0.31 [ 0.14, 0.67 ]
Van Den Berg 2007 111 57 -0.40048 (0.27138) 10.3 % 0.67 [ 0.39, 1.14 ]
White 2014 114 7 -0.42527 (0.76571) 2.4 % 0.65 [ 0.15, 2.93 ]
White 2014 120 13 -1.96571 (0.66127) 3.1 % 0.14 [ 0.04, 0.51 ]
Total (95% CI) 8351 1148 100.0 % 0.57 [ 0.45, 0.73 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 26.63, df = 18 (P = 0.09); I2 =32%
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 1 HCV incidence
adjusted analyses by region.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 6 High NSP coverage versus no/low NSP coverage
Outcome: 1 HCV incidence adjusted analyses by region
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 North America
Bruneau 2015 [pers comm] 183 102 -0.35667 (0.225685) 26.1 % 0.70 [ 0.45, 1.09 ]
Hagan 1999 161 26 0.270027 (0.260108) 25.2 % 1.31 [ 0.79, 2.18 ]
Patrick 2001 93 62 0.940007 (0.408327) 21.2 % 2.56 [ 1.15, 5.70 ]
Subtotal (95% CI) 437 190 72.5 % 1.25 [ 0.63, 2.46 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 8.70, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.64 (P = 0.53)
2 Europe
Hope 2011 101 14 -1.27297 (0.633905) 15.3 % 0.28 [ 0.08, 0.97 ]
Palmateer 2014a 2396 392 -1.7148 (0.785616) 12.2 % 0.18 [ 0.04, 0.84 ]
Subtotal (95% CI) 2497 406 27.5 % 0.24 [ 0.09, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Total (95% CI) 2934 596 100.0 % 0.79 [ 0.39, 1.61 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 17.42, df = 4 (P = 0.002); I2 =77%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 7.64, df = 1 (P = 0.01), I2 =87%
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Analysis 6.2. Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 2 HCV incidence
adjusted analyses by study design.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 6 High NSP coverage versus no/low NSP coverage
Outcome: 2 HCV incidence adjusted analyses by study design
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Prospective cohorts
Patrick 2001 93 62 0.940007 (0.408327) 21.1 % 2.56 [ 1.15, 5.70 ]
Hagan 1999 161 26 0.270027 (0.260108) 26.0 % 1.31 [ 0.79, 2.18 ]
Bruneau 2015 [pers comm] 183 102 0.225685 (0.225685) 27.1 % 1.25 [ 0.81, 1.95 ]
Subtotal (95% CI) 437 190 74.1 % 1.44 [ 1.01, 2.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.49, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.04 (P = 0.042)
2 Cross-sectional surveys
Palmateer 2014a 2396 392 -1.7148 (0.785616) 11.3 % 0.18 [ 0.04, 0.84 ]
Hope 2011 101 14 -1.27297 (0.633905) 14.5 % 0.28 [ 0.08, 0.97 ]
Subtotal (95% CI) 2497 406 25.9 % 0.24 [ 0.09, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Total (95% CI) 2934 596 100.0 % 0.95 [ 0.50, 1.82 ]
Heterogeneity: Tau2 = 0.36; Chi2 = 14.70, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 11.92, df = 1 (P = 0.00), I2 =92%
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Analysis 7.1. Comparison 7 Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data,
Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 7 Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hagan 1999 161 26 0.270027 (0.26010814) 30.9 % 1.31 [ 0.79, 2.18 ]
Hope 2011 101 14 -1.27297 (0.633905) 22.4 % 0.28 [ 0.08, 0.97 ]
Palmateer 2014a 2396 392 -1.7148 (0.785616) 19.0 % 0.18 [ 0.04, 0.84 ]
Patrick 2001 93 0.94000727 (0.40832657) 62 27.7 % 2.56 [ 1.15, 5.70 ]
Total (95% CI) 2751 494 100.0 % 0.77 [ 0.28, 2.13 ]
Heterogeneity: Tau2 = 0.81; Chi2 = 14.63, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Sensitivity analysis: high NSP versus low/no NSP, excluding cross-sectional
surveys, Outcome 1 HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 8 Sensitivity analysis: high NSP versus low/no NSP, excluding cross-sectional surveys
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bruneau 2015 [pers comm] 183 102 -0.35667 (0.225685) 37.2 % 0.70 [ 0.45, 1.09 ]
Hagan 1999 161 26 0.270027 (0.260108) 35.4 % 1.31 [ 0.79, 2.18 ]
Patrick 2001 93 62 0.940007 (0.408327) 27.4 % 2.56 [ 1.15, 5.70 ]
Total (95% CI) 437 190 100.0 % 1.25 [ 0.63, 2.46 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 8.70, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.64 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 High NSP coverage versus low/no coverage, unadjusted estimates, Outcome 1
HCV incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 9 High NSP coverage versus low/no coverage, unadjusted estimates
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bruneau 2015 [pers comm] 183 102 -0.216136 (0.221199) 16.2 % 0.81 [ 0.52, 1.24 ]
Hagan 1999 161 26 0.350657 (0.404929) 14.1 % 1.42 [ 0.64, 3.14 ]
Hope 2011 101 14 -2.17253 (0.790184) 9.2 % 0.11 [ 0.02, 0.54 ]
Hope 2015 [pers comm] 917 3 -0.01005 (0.786869) 9.3 % 0.99 [ 0.21, 4.63 ]
Hope 2015 [pers comm] 917 2 -0.31471 (1.454621) 4.4 % 0.73 [ 0.04, 12.63 ]
Hope 2015 [pers comm] 916 2 -0.59784 (1.232121) 5.6 % 0.55 [ 0.05, 6.15 ]
Palmateer 2014a 2396 392 -1.34707 (0.611708) 11.4 % 0.26 [ 0.08, 0.86 ]
Patrick 2001 93 62 1.305627 (0.283051) 15.5 % 3.69 [ 2.12, 6.43 ]
Van Den Berg 2007 138 30 -0.47804 (0.374066) 14.4 % 0.62 [ 0.30, 1.29 ]
Total (95% CI) 5822 633 100.0 % 0.78 [ 0.39, 1.55 ]
Heterogeneity: Tau2 = 0.72; Chi2 = 37.14, df = 8 (P = 0.00001); I2 =78%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Low NSP coverage versus no coverage, Outcome 1 HCV incidence, adjusted
analyses.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 10 Low NSP coverage versus no coverage
Outcome: 1 HCV incidence, adjusted analyses
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hagan 1995 26 20 -1.9865 (0.766958) 9.3 % 0.14 [ 0.03, 0.62 ]
Hagan 1999 171 16 0.951658 (0.606068) 12.5 % 2.59 [ 0.79, 8.50 ]
Holtzman 2009 1149 139 0.398776 (0.22179) 24.9 % 1.49 [ 0.96, 2.30 ]
Maher 2015 315 53 0.444686 (0.29344) 22.3 % 1.56 [ 0.88, 2.77 ]
Mehta 2015 [pers comm] 316 8 -0.27444 (1.03044) 6.0 % 0.76 [ 0.10, 5.73 ]
Page 2015 [pers comm] 381 171 0.963174 (0.218058) 25.0 % 2.62 [ 1.71, 4.02 ]
Total (95% CI) 2358 407 100.0 % 1.43 [ 0.82, 2.49 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 16.20, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Low NSP coverage versus no NSP, unadjusted analysis, Outcome 1 HCV
incidence.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 11 Low NSP coverage versus no NSP, unadjusted analysis
Outcome: 1 HCV incidence
Study or subgroup anti-HCV negative HCV new cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hagan 1995 26 20 -2.09679 (0.778582) 5.1 % 0.12 [ 0.03, 0.57 ]
Hagan 1999 171 16 0.542324 (0.452855) 10.2 % 1.72 [ 0.71, 4.18 ]
Holtzman 2009 1149 139 0.198851 (0.179772) 18.1 % 1.22 [ 0.86, 1.74 ]
Maher 2015 315 53 0.620577 (0.290575) 14.6 % 1.86 [ 1.05, 3.29 ]
Mehta 2015 [pers comm] 316 8 0.322084 (1.075078) 3.0 % 1.38 [ 0.17, 11.35 ]
Page 2015 [pers comm] 381 0 1.036737 (0.218905) 16.9 % 2.82 [ 1.84, 4.33 ]
Thorpe 2002 324 29 0.254642 (0.392058) 11.7 % 1.29 [ 0.60, 2.78 ]
Van Den Berg 2007 139 29 0.444686 (0.384855) 11.9 % 1.56 [ 0.73, 3.32 ]
White 2014 102 25 0 (0.528692) 8.6 % 1.00 [ 0.35, 2.82 ]
Total (95% CI) 2923 319 100.0 % 1.41 [ 0.95, 2.09 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 21.21, df = 8 (P = 0.01); I2 =62%
Test for overall effect: Z = 1.71 (P = 0.088)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome
1 HCV incidence adjusted analyses.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 12 Combined OST and high/low NSP versus no OST and low/no NSP
Outcome: 1 HCV incidence adjusted analyses
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 High NSP coverage
Bruneau 2015 [pers comm] 183 102 -0.52763 (0.27035) 24.7 % 0.59 [ 0.35, 1.00 ]
Palmateer 2014a 2396 392 -2.99573 (0.73734) 13.5 % 0.05 [ 0.01, 0.21 ]
Van Den Berg 2007 151 17 -1.02165 (0.528005) 18.2 % 0.36 [ 0.13, 1.01 ]
Subtotal (95% CI) 2730 511 56.4 % 0.26 [ 0.07, 0.89 ]
Heterogeneity: Tau2 = 0.94; Chi2 = 9.99, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Low NSP coverage
Palmateer 2014a 2396 392 -0.52763 (0.420199) 20.9 % 0.59 [ 0.26, 1.34 ]
Van Den Berg 2007 123 45 0.157004 (0.348184) 22.7 % 1.17 [ 0.59, 2.32 ]
Subtotal (95% CI) 2519 437 43.6 % 0.87 [ 0.44, 1.68 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 5249 948 100.0 % 0.45 [ 0.22, 0.94 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 15.93, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Chi2 = 2.85, df = 1 (P = 0.09), I2 =65%
0.01 0.1 1 10 100
Favours combined OST-NSP Favours no OST-NSP
72Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 12.2. Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome
2 HCV incidence unadjusted analyses.
Review: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Comparison: 12 Combined OST and high/low NSP versus no OST and low/no NSP
Outcome: 2 HCV incidence unadjusted analyses
Study or subgroup anti-HCV negative new HCV cases log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Combined OST and high NSP versus no OST and low/no NSP
Bruneau 2015 [pers comm] 183 102 -0.46204 (0.270896) 20.3 % 0.63 [ 0.37, 1.07 ]
Hope 2011 108 7 -1.75254 (1.115853) 4.8 % 0.17 [ 0.02, 1.54 ]
Palmateer 2014a 2396 392 -1.42712 (0.457081) 14.8 % 0.24 [ 0.10, 0.59 ]
Van Den Berg 2007 151 17 -1.89712 (0.501559) 13.7 % 0.15 [ 0.06, 0.40 ]
Subtotal (95% CI) 2838 518 53.6 % 0.29 [ 0.13, 0.65 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 8.42, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 3.00 (P = 0.0027)
2 Combined OST and low NSP versus no OST and low/no NSP
Hope 2011 103 12 0.080043 (0.64301) 10.5 % 1.08 [ 0.31, 3.82 ]
Palmateer 2014a 2396 392 -0.73397 (0.350975) 17.8 % 0.48 [ 0.24, 0.95 ]
Van Den Berg 2007 123 45 0.039221 (0.345081) 18.0 % 1.04 [ 0.53, 2.05 ]
Subtotal (95% CI) 2622 449 46.4 % 0.76 [ 0.44, 1.33 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 2.84, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 5460 967 100.0 % 0.47 [ 0.27, 0.80 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 15.87, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Chi2 = 3.71, df = 1 (P = 0.05), I2 =73%
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Table 1. Risk of bias of included studies (Continued)
Aitken 2015
[pers comm]
Critical Critical Serious No info Critical Low No info Critical
Bruneau
2015 [pers
comm]
Moderate Serious Moderate No info No info Low Low Serious
Craine 2009 Serious Serious Serious No info Serious Low Low Serious
Crofts 1997 Critical Serious Low No info Serious Serious Low Critical
Hagan 1995 Serious Serious Serious No info Low Low Low Serious
Hagan 1999 Moderate Serious Low No info Low Low Low Serious
Holtzman
2009
Serious Serious Moderate No info No info Low Low Serious
Hope 2011 Moderate Moderate Serious No info Low Low Low Serious
Hope 2015
[pers comm]
Moderate Moderate Serious No info No info Low Low Serious
Judd 2015
[pers comm]
Moderate Critical Critical No info Critical Low Low Critical
Lucidarme
2004
Moderate Serious Serious No info Serious Low Low Serious
Maher 2015 Moderate Serious Serious No info No info Low Low Serious
Mehta 2015
[pers comm]
Moderate No info No info No info No info Low Low No info
Nolan 2014 Serious Serious Moderate No info Low Low Low Serious
Page 2015
[pers comm]
Moderate No info No info No info No info Low Low No info
Palmateer
2014a
Serious Serious Moderate No info Serious Low Low Serious
Patrick 2001 Serious Moderate Serious No info Serious Low Low Serious
Rezza 1996 Serious Low Serious No info Critical Low Low Critical
Roy 2007 Serious Serious Serious No info Critical Low Low Critical
Ruan 2007 Critical Critical Serious No info Serious Low Low Critical
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Table 1. Risk of bias of included studies (Continued)
Spittal 2012 Serious Serious Moderate No info Low Low Low Serious
Thiede
2000
Moderate Moderate Low No info Low Low Low Moderate
Thorpe
2002
Serious Serious Serious No info Moderate Low Low Serious
Tsui 2014 Moderate Moderate Low No info Moderate Low Low Moderate
Vallejo 2015 Serious Serious Low No info Serious Low Low Serious
Van Beek
1998
Critical Serious Serious No info Critical Low Low Critical
Van Den
Berg 2007
Serious Serious Moderate No info Serious Low Low Serious
White 2014 Moderate Serious Moderate No info No info Low Low Serious
Table 2. Univariable meta-regression analysis for studies measuring impact of current use of OST on HCV incidence
Variable Studies Univariable rate ratio
(95% CI)
Ratio of rate ratios
(95% CI)
P value Tau2
Geographic region
Europe 8 0.51 (0.37-0.70) 1.0 (ref ) - -
Australia 5 0.55 (0.28-1.11) 1.12 (0.52-2.41) - -
North America 6 0.69 (0.44-1.08) 1.42 (0.73-2.78) 0.53 0.10
Site of recruitment
Service attenders 12 0.67 (0.49-0.92) 1.0 (ref ) - -
Community 7 0.49 (0.33-0.73) 0.73 (0.42-1.27) 0.256 0.06
Study design
Cross-sectional 4 0.51 (0.31-0.85) 1.0 - -
Prospective cohort 15 0.58 (0.43-0.77) 1.12 (0.48-2.61) 0.784 0.10
Females 17 - 1.59 (1.13-2.29) 0.01 0.04
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Table 2. Univariable meta-regression analysis for studies measuring impact of current use of OST on HCV incidence (Con-
tinued)
Prison experience 11 - 1.057 (0.61-1.79) 0.821 0.43
Experience of
homelessness
12 - 1.08 (0.83-1.40) 0.521 0.23
Injection of stimu-
lants
12 - 0.89 (0.65-1.22) 0.373 0.17
Daily injection 7 - 0.88 (0.64-1.22) 0.373 0.17
CI: confidence interval; HCV: hepatitis C virus; OST: opioid substitution therapy.
Table 3. Univariable meta-regression analysis for studies measuring impact of high NSP coverage on HCV incidence
Variable Studies Univariable rate ratio
(95%CI)
Ratio of rate ratios
(95%CI)
P value Tau2
Geographic region
Europe 5 0.44 (0.24-0.80) 1.0 (Ref ) - -
North America 3 1.58 (0.57-4.42) 3.73 (0.95-14.7) 0.057 0.41
Recruitment site
Service attenders 3 0.67 (0.28-1.59) 1.0 (Ref ) - -
Community 5 0.82 (0.29-2.32) 0.76(0.12-4.88) 0.74 0.89
Study design
Cross-sectional sur-
vey
3 0.34 (0.16-0.75) 1.0 (Ref ) - -
Prospective cohort 4 1.26 (0.55-2.93) 3.53 (0.78-15.86) 0.087 0.48
Females 7 - 2.97(0.38-23.1) 0.24 0.87
Prison experience 3 - NA - -
Experience of
homelessness
6 - 1.01 (0.38-2.67) 0.976 1.53
Injection of stimu-
lants
7 - 1.08 (0.47-2.51) 0.827 1.15
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Table 3. Univariable meta-regression analysis for studies measuring impact of high NSP coverage on HCV incidence (Con-
tinued)
Daily injection 5 - 3.66 (0.22-61.3) 0.239 1.15
CI: confidence interval; HCV: hepatitis C virus; NSP: needle syringe programmes.
A P P E N D I C E S
Appendix 1. Search strategies to identify studies that measure the impact of NSP/OST on HCV
incidence
Cochrane Drug and Alcohol Group Specialised Register (CRS)
1. (HCV) AND (INREGISTER)
2. (“hepatitis C”) AND (INREGISTER)
3. (“hep C”) AND (INREGISTER)
4. #1 OR #2 OR #3
CENTRAL, DARE, NHSEED and HTA (Cochrane Library)
1. MeSH descriptor: [Needle-Exchange Programs] explode all trees
2. MeSH descriptor: [Community Pharmacy Services] explode all trees
3. ((needle* or syringe* or inject*) near/3 exchange):ti,ab,kw (Word variations have been searched)
4. MeSH descriptor: [Harm Reduction] explode all trees
5. (harm near/2 reduc*):ti,ab,kw (Word variations have been searched)
6. (needle* or syringe* or inject*) near/3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*):ti,ab,kw
(Word variations have been searched)
7. (needle* or syringe* or inject*) near/3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or
pharmacy or pharmacies or unit or units or room*):ti,ab,kw (Word variations have been searched)
8. (needle* or syringe* or inject* or slot or dispensing or vending) near/3 (machine* or (peer next distrib*)):ti,ab,kw (Word
variations have been searched)
9. #1 or #2 or #3 or #4 or #5 or #5 or #6 or #7 or #8
10. MeSH descriptor: [Substance Abuse, Intravenous] explode all trees
11. ((substance* or drug* or opiate* or opioid* or heroin* or morphin* or morfin* or narcot*) near/6 (use* or abus* or misuse* or
addict* or depend*)):ti,ab,kw (Word variations have been searched)
12. (substance* or drug) and (inject* or intravenous):ti,ab,kw (Word variations have been searched)
13. #10 or #11 or #12
14. MeSH descriptor: [Opiate Substitution Treatment] explode all trees
15. MeSH descriptor: [Methadone] explode all trees
16. MeSH descriptor: [Buprenorphine] explode all trees
17. (substitut* or maint*) near/2 (treatment or therapy):ti,ab,kw (Word variations have been searched)
18. (methadone or buprenorphine or subutex or suboxone):ti,ab,kw (Word variations have been searched)
19. #13 or #14 or #15 or #16 or #17 or #18
20. #9 or #19
21. MeSH descriptor: [Hepatitis C] explode all trees
22. (hepatitis next C) or (hep next C):ti,ab,kw (Word variations have been searched)
23. HCV:ti,ab
24. #21 or #22 or #23
25. #13 and #20 and #24
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MEDLINE, PsycINFO and Global Health (Ovid)
1. Needle-Exchange Programs/
2. Community pharmacy services/
3. ((needle* or syringe* or inject*) adj3 exchange).ab,ti.
4. Harm Reduction/
5. (harm adj reduc*).ab,ti.
6. ((needle* or syringe* or inject*) adj3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*)).ab,ti.
7. ((needle* or syringe* or inject*) adj3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or
pharmacy or pharmacies or unit or units or room*)).ab,ti.
8. ((needle* or syringe* or inject* or slot or dispensing or vending) adj3 (machine* or (peer adj distrib*))).ab,ti.
9. or/1-8
10. Substance Abuse, Intravenous/
11. (substance$ or drug$).ab,ti.
12. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.
13. (inject$ or intravenous).ab,ti.
14. 10 or (11 and 12) or (11 and 13)
15. opiate substitution treatment/
16. methadone/
17. buprenorphine/
18. (((substitut* or maint*) adj2 (treatment or therapy)) or methadone or buprenorphine or subutex or suboxone).ab,ti.
19. or/15-18
20. exp Hepatitis C/
21. (hepatitis-c or or hep c or hcv).ab,ti.
22. 20 or 21
23. (9 or 19) and 14 and 22
EMBASE (embase.com)
’substance abuse’/expOR ’substance abuse’ OR ((substance* OR drug* OR opiate* OR opioid* OR heroin* ORmorphin* ORmorfin*
OR narcot*) NEAR/6 (use* OR abus* OR misuse* OR addict* OR depend*)):ab,ti OR ((substance* OR drug*) NEAR/6 (inject*
OR intravenous)):ab,ti AND (’hepatitis c’/exp OR ’hepatitis-c’:ab,ti OR ’hep c’:ab,ti OR hcv:ab,ti) AND (’preventive health service’/
exp OR ((needle* OR syringe* OR inject*) NEAR/3 exchange):ab,ti OR ’harm reduction’/exp OR (harm NEAR/2 reduc*):ab,ti OR
((needle* OR syringe* OR inject*) NEAR/3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*)):
ab,ti OR ((needle* OR syringe* OR inject*) NEAR/3 (program* OR service* OR center* OR centre* OR scheme* OR facility OR
facilities OR area* OR pharmacy OR pharmacies OR unit OR units OR room*)):ab,ti OR ((needle* OR syringe* OR inject* OR slot
OR dispensing OR vending) NEAR/3 (machine* OR peer)):ab,ti OR ’opiate substitution treatment’/exp OR ’methadone’/exp OR
methadone:ab,ti OR ’buprenorphine’/exp OR ’buprenorphine’:ab,ti OR ((substitut* OR maint*) NEAR/2 (treatment OR therapy)):
ab,ti OR subutex:ab,ti OR suboxone:ab,ti)
CINAHL (EBSCO)
1. (MH “Needle Exchange Programs”)
2. TI((needle* OR syringe*OR inject*) N3 exchange) OR AB(needle* OR syringe* OR inject*) N3 exchange)
3. (MH “Harm Reduction”)
4. TI (harm N2 reduc*) OR AB (harm N2 reduc*)
5. TI ((needle* OR syringe* OR inject*) N3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR pack*)
) OR AB ( TI(needle* OR syringe* OR inject*) N3 (suppl* OR access* OR provision OR provid* OR distribut* OR dispens* OR
pack*))
6. TI ((needle* OR syringe* OR inject*) N3 (program* OR service* OR center* OR centre* OR scheme* OR facility OR facilities
OR area* OR pharmacy OR pharmacies OR unit OR units OR room*)) OR AB ( (needle* OR syringe* OR inject*) N3 (program*
OR service* OR center* OR centre* OR scheme* OR facility or facilities OR area* OR pharmacy OR pharmacies OR unit OR units
OR room*))
7. TI (((needle* OR syringe* OR inject* OR slot OR dispensing OR vending) N3 (machine*OR (peer N2 distrib*)))) OR AB (
((needle* OR syringe* OR inject* OR slot OR dispensing OR vending) N3 (machine* OR (peer N2 distrib*))))
8. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
9. (MH “Substance Abuse, Intravenous”)
78Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
10. TI ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus*
OR misuse* OR addict* OR depend*))
11. AB ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus*
OR misuse* OR addict* ORdepend*))
12. TI (substance* OR drug*) AND TI (inject* OR intravenous)
13. AB(substance* OR drug* ) AND AB( inject* OR intravenous)
14. S9 OR S10 OR S11 OR S12 OR S13
15. (MH “Methadone”) OR (MH “Buprenorphine”)
16. TI (methadone or buprenorphine or subutex or suboxone) OR AB (methadone or buprenorphine or subutex or suboxone)
17. TX (substitut* or maint*) N2 (treatment or therapy)
18. S15 OR S16 OR S17
19. (MH “Hepatitis C+”)
20. TI ( “hepatitis-c” or “hep c” or hcv ) OR AB ( “hepatitis-c” or “hep c” or hcv )
21. S19 OR S20
22. S8 OR S18
23. S14 AND S21 AND S22
Web of Science (THOMSON REUTERS)
1. TOPIC: (((needle* OR syringe* OR inject*) NEAR/3 exchange))
2. TOPIC: (harm NEAR/2 reduc*)
3. TOPIC: (((needle* OR syringe* OR inject*) NEAR/3 (suppl* OR access* OR provision OR provid* OR distribut* OR
dispens* OR pack*)))
4. TOPIC: ((needle* or syringe* or inject*) near/3 (program* or service* or center* or centre* or scheme* or facility or facilities or
area* or pharmacy or pharmacies or unit or units or room*))
5. TOPIC: ((needle* or syringe* or inject* or slot or dispensing or vending) NEAR/3 (machine* orpeer))
6. #5 OR #4 OR #3 OR #2 OR #1
7. TOPIC: (((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use*
OR abus* OR misuse* OR addict* OR depend*)))
8. TOPIC: ((substance* or drug) and (inject* or intravenous))
9. #8 OR #7
10. TOPIC: ((substitut* or maint*) near/2 (treatment or therapy))
11. TOPIC: ((methadone or buprenorphine or subutex or suboxone))
12. #11 OR #10
13. TOPIC: (“Hepatitis C”)
14. TOPIC: (“Hep C”)
15. TOPIC: (HCV)
16. #15 OR #14 OR #13
17. #12 OR #6
18. #17 AND #16 AND #9
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=All years
Appendix 2. Search strategies to identify longitudinal studies
MEDLINE, PsycINFO & Global Health (Ovid)
1. Substance Abuse, Intravenous/
2. (substance$ or drug$).ab,ti.
3. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.
4. (inject$ or intravenous).ab,ti.
5. 1 or (2 and 3) or (2 and 4)
6. exp Hepatitis C/
7. (hepatitis-c or hcv).ab,ti.
8. (HCV adj2 seroconvers$).ti,ab.
9. (HCV adj2 transmission).ti,ab.
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10. or/6-9
11. exp Cohort Studies/
12. exp Longitudinal Studies/
13. (prospective or longitudinal or cohort).ti,ab.
14. or/11-13
15. 5 and 10 and 14
16. Animals/
17. 15 not 16
Embase (embase.com)
’substance abuse’/exp OR ((substance* OR drug* OR opiate* OR opioid* OR heroin* ORmorphin* ORmorfin* OR narcot*) NEAR/
6 (use* OR abus* OR misuse* OR addict* OR depend*)):ab,ti OR ((substance* OR drug*) NEAR/6 (inject* OR intravenous)):ab,ti
AND (’hepatitis c’/exp OR ’hepatitis-c’:ab,ti OR ’hep c’:ab,ti ORhcv:ab,ti) AND (’cohort analysis’/exp OR ’longitudinal study’/exp
OR prospective:ab,ti OR longitudinal:ab,ti OR cohort:ab,ti)
CINAHL (EBSCO)
1. (MH “Substance Abuse, Intravenous”)
2. TI ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus*
OR misuse* OR addict* OR depend*))
3. AB ((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) N6 (use* OR abus*
OR misuse* OR addict* OR depend*))
4. TI ( substance* OR drug* ) AND TI ( inject* OR intravenous )
5. AB( substance* OR drug* ) AND AB( inject* OR intravenous )
6. S1 OR S2 OR S3 OR S4 OR S5
7. (MH “Hepatitis C+”)
8. TI ( “hepatitis-c” or “hep c” or hcv ) OR AB ( “hepatitis-c” or “hep c” or hcv )
9. S7 OR S8
10. (MH “Prospective Studies+”)
11. TI ( prospective or longitudinal or cohort ) OR AB ( prospective or longitudinal or cohort )
12. S10 OR S11
13. S6 AND S9 AND S12
Web of Science (THOMSON REUTERS)
1. TOPIC: (((substance* OR drug* OR opiate* OR opioid* OR heroin* OR morphin* OR morfin* OR narcot*) NEAR/6 (use*
OR abus* OR misuse* OR addict* OR depend*)))
2. TOPIC: ((substance* or drug) and (inject* or intravenous))
3. #1 OR #2
4. TOPIC: (“Hepatitis C”)
5. TOPIC: (“Hep C”)
6. TOPIC: (HCV)
7. #4 OR #5 OR #6
8. TOPIC: (prospective or longitudinal or cohort)
9. #3 AND #7 AND #8
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=All years
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Appendix 3. Criteria for risk of bias assessment for RCTs
Item Judgment Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgment of the
clinician; results of a laboratory test or a series of tests; availability of the
intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgment of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal alloca-
tion: central allocation (including telephone, web-based, and pharmacy-
controlled, randomisation); sequentially-numbered drug containers of
identical appearance; sequentially-numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgment of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgment
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgment of low or high risk
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(Continued)
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers ensured and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgment of low or high risk
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgment of low or high risk
6.Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgment of low or high risk
7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop out
Low risk No missing outcome data
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias)
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically-relevant
impact on the intervention effect estimate
For continuous outcome data, plausible effect size (difference inmeans or
standardised difference in means) among missing outcomes not enough
to have a clinically-relevant impact on observed effect size
Missing data have been imputed using appropriate methods
All randomised patients are reported/analysed in the group they were
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(Continued)
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across in-
tervention groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough to
induce clinically relevant bias in observed effect size
’As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient information to permit judgment of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of dropout not reported for each group)
8 Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
High risk Not all of the study’s pre-specified primary outcomes have been reported
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not pre-specified
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgment of low or high risk
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Appendix 4. Criteria for risk of bias assessment for observational studies
Domain Judgment Description
Bias due to confounding Low risk (the study is comparable to awell-
performed randomised trial with regard to
this domain)
No confounding expected
Moderate risk (the study is
sound for a non-randomised study with re-
gard to this domain but cannot be consid-
ered comparable to a well performed ran-
domised trial)
Confounding expected, all knowncritically
important confounding domains appropri-
ately measured and adjusted for;
and
Reliability and validity of measurement of
a critically important domains were suffi-
cient that we do not expect serious residual
confounding
Serious risk (the study has some important
problems)
At least one known critically important do-
main not appropriately measured, or not
adjusted for;
or
Reliability or validity of measurement of
a critically important domain was low
enough that we expect serious residual con-
founding
Critical risk (the study is too problematic
to provide any useful evidence on the effects
of intervention)
Confounding inherently not controllable,
or use of negative controls strongly suggests
unmeasured confounding
No information on which to base a judg-
ment about risk of bias for this domain
No information on whether confounding
might be present
Bias in selection of participants into the
study
Low risk All participants who would have been el-
igible for the target trial were included in
the study and start of follow-up and start
of intervention coincide for all participants
Moderate risk Selection into the study may have been re-
lated to intervention and outcome, but the
authors used appropriatemethods to adjust
for the selection bias;
or
Start of follow-up and start of intervention
do not coincide for all participants, but the
proportion of participants for which this
was the case was too low to induce im-
portant bias; the authors used appropriate
methods to adjust for the selection bias; or
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the review authors are confident that the
rate (hazard) ratio for the effect of interven-
tion remains constant over time
Serious risk Selection into the study was related to in-
tervention and outcome;
or
Start of follow-up and start of intervention
do not coincide, and a potentially impor-
tant amount of follow-up time is missing
from analyses, and the rate ratio is not con-
stant over time
Critical risk Selection into the studywas strongly related
to intervention and outcome;
or
A substantial amount of follow-up time is
likely to be missing from analyses, and the
rate ratio is not constant over time
No information No information is reported about selection
of participants into the study or whether
start of follow-up and start of intervention
coincide
Bias in measurement of interventions Low risk Intervention status is well defined and
based solely on information collected at the
time of intervention
Moderate risk Intervention status is well defined but some
aspects of the assignments of intervention
status were determined retrospectively
Serious risk Intervention status is not well defined, or
major aspects of the assignments of inter-
vention status were determined in a way
that could have been affected by knowledge
of the outcome
Critical risk (Unusual) An extremely high amount of
misclassification of intervention status, e.g.
because of unusually strong recall biases
No information No definition of intervention or no expla-
nation of the source of information about
intervention status
Bias due to departures from intended
interventions
Low risk No bias due to departure from the in-
tended intervention is expected, for exam-
ple if both the intervention and compara-
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(Continued)
tor are implemented over a short time pe-
riod, and subsequent interventions are part
of routine medical care, or if the specified
comparison relates to initiation of interven-
tion regardless of whether it is continued
Moderate risk Bias due to departure from the intended
intervention is expected, and switches, co-
interventions, and some problems with in-
tervention fidelity are appropriately mea-
sured and adjusted for in the analyses. Al-
ternatively, most (but not all) departures
from intended intervention reflect the nat-
ural course of events after initiation of in-
tervention
Serious risk Switches in treatment, co-interventions, or
problems with implementation fidelity are
apparent and are not adjusted for in the
analyses
Critical risk Substantial departures from the intended
intervention are present and are not ad-
justed for in the analysis.
No information No information is reported on whether
there is departure from the intended inter-
vention
Bias due to missing data Low risk Data were reasonably complete;
or
Proportions and reasons of missing par-
ticipants were similar across intervention
groups;
or
Analyses that addressed missing data are
likely to have removed any risk of bias
Moderate risk Proportions of missing participants differ
across
interventions or reasons for missingness
differ minimally across interventions;
and
Missing data were not addressed in the
analysis.
Serious risk Proportions of missing participants differ
substantially across interventions or reasons
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for missingness differ substantially across
interventions;
and
Missing data were addressed inappropri-
ately in the analysis;
or
The nature of the missing data means that
the risk of
bias cannot be removed through appropri-
ate analysis.
Critical risk (Unusual) There were critical differences
between
interventions in participants with missing
data that were not, or could not, be ad-
dressed through appropriate analysis
No information No information is reported about missing
data or the
potential for data to be missing
Bias in measurement of outcomes Low risk The methods of outcome assessment were
comparable across intervention groups;
and
The outcome measure was unlikely to be
influenced by knowledge of the interven-
tion received by study participants (i.e. is
objective) or the outcome assessors were
unaware of the intervention received by
study participants;
and
Any error in measuring the outcome is un-
related to
intervention status.
Moderate risk The methods of outcome assessment were
comparable across intervention groups;
and
The outcomemeasure is onlyminimally in-
fluenced by knowledge of the intervention
received by study
participants;
and
Any error inmeasuring the outcome is only
minimally related to intervention status
Serious risk The methods of outcome assessment were
not comparable across intervention groups;
or
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(Continued)
The outcome measure was subjective (i.e.
likely to be
influenced by knowledge of the interven-
tion received by study participants) andwas
assessed by outcome assessors aware of the
intervention received by study participants;
or
Error inmeasuring the outcomewas related
to intervention status
Critical risk The methods of outcome assessment were
so different that they cannot reasonably be
compared across intervention groups
No information No information is reported about the
methods of outcome assessment
Bias in selection of the reported result Low risk There is clear evidence (usually through ex-
amination of a pre-registered protocol or
statistical analysis plan) that all reported re-
sults correspond to all intended outcomes,
analyses and sub-cohorts
Moderate risk The outcome measurements and analyses
are consistent with an a priori plan; or are
clearly defined, and internally and exter-
nally consistent;
and
There is no indication of selection of the re-
ported analysis from among multiple anal-
yses;
and
There is no indication of selection of the
cohort or subgroups for analysis and report-
ing on the basis of the results
Serious risk Outcome measurements or analyses are in-
ternally or
externally inconsistent;
or
There is a high risk of selective reporting
from among
multiple analyses;
or
The cohort or subgroup is selected from a
larger study for analysis and appears to be
reported on the basis of the results
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(Continued)
Critical risk There is evidence or strong suspicion of se-
lective reporting of results, and the unre-
ported results are likely to be substantially
different from the reported results
No information There is too little information to make a
judgment, for example if only an abstract
is available for the study
Overall judgment about risk of bias Low risk The study is judged to be at low risk of bias
for all domains
Moderate risk The study is judged to be at low or moder-
ate risk of bias for all domains
Serious risk The study is judged to be at serious risk
of bias in at least one domain, but not at
critical risk of bias in any domain
Critical risk The study is judged to be at critical risk of
bias in at least one domain
No information There is no clear indication that the study
is at
serious or critical risk of bias and there is
a lack of information in one or more key
domains of bias (a judgment is required for
this)
H I S T O R Y
Date Event Description
20 January 2016 Amended External source of support added
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C O N T R I B U T I O N S O F A U T H O R S
Lucy Platt led the writing of the protocol, the screening of papers, data extraction, analyses and write-up of the review.
Silvia Minozzi contributed to prepare the protocol, assessed risk of bias of the included studies and contributed to writing the text of
the review.
Jennifer Reed contributed to the literature search, ’Risk of bias’ assessment and data extraction.
Peter Vickerman contributed to the development of the protocol, interpretation of findings and the write-up of text of the review.
Holly Hagan contributed to the ’Risk of bias’ assessment, the analysis plan and interpretation of findings and the write-up of review
text.
Clare French led on the ’Risk of bias’ assessment.
Ashly Jordan contributed to the risk of bias assessment and interpretation of findings.
Louisa Degenhardt contributed to the development of the protocol as well as the write-up of the review.
Vivian Hope contributed to the interpretation of findings and write-up of the review.
Sharon Hutchinson contributed to the interpretation of findings and write up of the review.
Lisa Maher contributed to the development of the protocol, the identification of unpublished data, the interpretation of findings and
write-up of the review.
Norah Palmateer contributed to the development of the protocol and write-up of the review.
Avril Taylor contributed to the development of the protocol and write-up of the review.
Julie Bruneau contributed to the identification of unpublished data and the write-up of the review.
Matthew Hickman contributed to the development of the protocol, interpretation of findings and the write-up of text of the review.
D E C L A R A T I O N S O F I N T E R E S T
Lucy Platt: none known.
Jennifer Reed: none known.
Silvia Minozzi: none known.
Peter Vickerman: received research grant funding off Gilead for doing work unrelated to this project.
Holly Hagan: none known.
Clare French: none known.
Ashly Jordan: none known.
Louisa Degenhardt: I have received untied educational grants from Reckitt Benckiser for the postmarketing surveillance of buprenor-
phine-naloxone tablets and soluble film (2006 to 2013), the development of an opioid-related behaviour scale (2010), and from
Mundipharma for the conduct of postmarketing surveillance studies following the introduction of a new formulation of oxycodone in
Australia. All such studies’ design, conduct and interpretation of findings are the work of the investigators; the funders had no role in
these. They had no knowledge of this work.
Vivian Hope: none known.
Sharon Hutchinson: outside the submitted work, received honoraria from pharma (Abbvie and Gilead) for speaking at conferences/
meetings on the epidemiology and treatment of HCV infection.
Lisa Maher: none known.
Norah Palmateer: none known.
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Avril Taylor: the Scottish Government funded the Needle Exchange Surveillance Initiative. Some of the data from this is used in the
paper under consideration.
Julie Bruneau: outside the submitted work, received honoraria from pharma (Merck and Gilead) as advisor on the treatment of HCV
infection among people who inject drugs.
Matthew Hickman: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute of Health Research (NIHR), UK.
The project was funded by the NIHR’s Public Health Research Programme (grant number: 12/3070/13). Clare French was funded
by the NIHR Health Protection Research Unit in Evaluation of Interventions at University of Bristol (grant number: HPRU-2012-
10026). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health
or Public Health England.
• European Commission Drug Prevention and Information Programme (DIPP) Grant “Treatment as Prevention in Europe:
Model Projections of Impact And Strengthening Evidence Base On Intervention Coverage and Effect and HCV Morbidity”. [JUST/
2013/DPIP/AG/4812], Other.
• National Institutes of Health/ National Institute on Drug Abuse (NIDA), USA.
Holly Hagan, Ashly Jordan and Jennifer Reed are supported by NIH-NIDA grant [1 R01 DA034637]
• Lisa Maher is supported by an Australian National Health and Medical Research Council Senior Research Fellowship, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added a final review author, Prof Julie Bruneau, who contributed some of the unpublished data and advised on the review
analyses and write-up.
We have changed the title to refer to opioids instead of opiates. Opioid encompasses synthetic opiates as well as those derived from
opium, whereas opiates just include drugs derived from opium.
We added in another control intervention that included low coverage of NSP. This became necessary as it was clear following data
extraction that many comparisons were made against this intervention exposure.
We also added to the description of the ’Risk of bias’ assessment following its application. When the protocol was first published the
tool was being piloted, and it was updated during the course of the review. We adapted our protocol to reflect these changes. We also
added in additional confounders to be extracted from the protocol, since after extracting the first few papers it became clear that we
had omitted relevant confounders.
We updated our approach to dealing with measures of treatment effect to reflect the dominant effect estimates that we were extracting.
We treated odds ratios as an approximation of the risk ratio despite the variation in HCV incidence. We checked the legitimacy of this
approach in a sensitivity analysis, excluding studies reporting odds ratios only.
We excluded studies where data regarding drug treatment or NSP were missing or unavailable from the analysis but not the review. We
updated the review to clarify this point.
The subgroup analysis differed from that specified in the review protocol since there was insufficient information to assess impact by
type of NSP, frequency of injecting, dose of OST, duration or age, ethnicity of participants. We did not assess impact by recruitment site
of participants either since most studies recruited across multiple sites and methods, making it difficult to clearly differentiate methods.
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The sensitivity analysis differed from that specified in the protocol in several ways. We did not exclude studies that reported incident
rate ratios as effect estimates, since only a few studies used incident rate ratios. Instead we removed estimates derived from unpublished
datasets as part of our sensitivity analyses since more estimates were derived in this way, making them a more substantive part of the
analysis. The original protocol also stated that we would exclude studies that only assessed the impact of the intervention at baseline.
We did this in the review but changed the wording to say that we excluded studies that used odds ratios as effect estimates and were
cross-sectional in design. This is the same as excluding baseline measures only, but we wanted to more clearly specify that the sensitivity
analysis had explored the effect of pooling different study designs.
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